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ABSTRACT 
 
 
The presence of stereogenic atoms in many biomolecules endows life with the 
property of chirality, making it possible that a mirror-image biological universe could 
exist.  This body of work explores avenues to, and uses for, mirror-image biological 
systems.  Particular attention is placed on the applications of mirror-image biology in the 
areas of drug discovery and synthetic biology.   
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CHAPTER 1 
 
 
PROLEGOMENON 
 
 
 The unifying theme of this thesis is the use of mirror-image proteins for drug 
discovery (via mirror-image phage display) and synthetic biology applications.   
 Chapter 2 serves as a general introduction by putting our mirror-image phage 
display efforts in the larger context of peptidomimetic drug discovery, highlighting the 
advantages of D-peptides as therapeutics, and describing methods for their discovery via 
genetically-encoded, library-based screening techniques.  Chapter 2 also provides an 
introduction to strategies for the synthesis of mirror-image proteins for use as display 
targets and proposes some exciting future directions for the use of mirror-image proteins 
in the field of synthetic biology. 
 Chapter 3 provides a more detailed look at the D-peptide discovery process by 
describing the design of a third-generation D-peptide HIV-1 entry inhibitor.  This was 
achieved through the optimization of a second-generation D-peptide entry inhibitor 
(PIE7) by structure-guided phage display and improvement of the geometry of PEG 
crosslinkers used to oligomerize the peptide into dimers and trimers.  The work 
culminated in the development of third-generation D-peptide (PIE12-trimer) that exhibits 
dramatically higher affinity for its binding site, improved potency, and a higher barrier to 
resistance. 
 Chapter 4 sets forth the current state of a project aiming to elucidate resistance 
! 2 
mechanisms employed by HIV against D-peptide entry inhibitors.  It describes our 
methodology to comprehensively characterize the genetic makeup of resistant viral 
populations through the use of both traditional Sanger and deep sequencing technologies, 
and describes the biochemical characterization of a resistance mechanism against the D-
peptides PIE12-trimer and cholesterol-conjugated PIE12-trimer.  This chapter concludes 
with a discussion of strategies to overcome resistance. 
 Chapter 5 describes the extension of our D-peptide discovery process to new targets, 
describing initial work towards the development of D-peptide entry inhibitors against 
Ebola virus.  Although Ebola has a similar entry mechanism to HIV, Ebola viral fusion 
occurs in the endosomal compartment versus at the cell surface (HIV).  This imposes the 
additional challenge of targeting peptides to the endosome. Chapter 5 presents work on 
the design, synthesis, and biophysical characterization of Ebola targets and preliminary 
target validation via phage display methods.   
 Chapter 6 addresses the challenge of mirror-image protein synthesis. Because 
mirror-image drug discovery and mirror-image synthetic biology are currently dependent 
upon our ability to successfully chemically assemble mirror-image proteins, robust 
methods for their construction are a priority.  Work presented in this chapter pushes the 
limits of current synthetic protein assembly methodologies in the total chemical synthesis 
of a 312 residue protein (dapA) in both L- and D- chiralities (the largest synthetic 
proteins in either chirality to date).  dapA was chosen for this study because of its 
dependence upon the GroEL/ES chaperone system for folding both in vitro and in vivo 
under physiological conditions.  After we demonstrated that our synthetic constructs were 
active by identifying nonphysiological buffer conditions that promoted folding, we used 
! 3 
the L- and D- enantiomers of dapA to probe for chiral specificity in the GroEL/ES 
protein-folding machinery.  !
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INTRODUCTION
I
n drug discovery and development, peptide therapeutics
have many advantages. Their polymeric nature makes
synthesis straightforward, especially when compared
with the synthetic schemes typically utilized for small
molecules. Peptides are generally easier and less expensive
to produce than recombinant proteins. Peptide therapeutics
can also be more specific (and less toxic) than small mole-
cules and excel at the challenging problem of disrupting large
protein–protein interaction interfaces (i.e., ‘‘undruggable’’
targets). Due to advancements in genomics and proteomics,
a plethora of natural peptide ligand sequences for important
drug targets are available and provide a sensible starting
point for the rational development of therapeutic com-
pounds. In addition, a host of mature and emerging library-
based screening techniques provides a means to rapidly dis-
cover novel peptide sequences with specific binding proper-
ties.
Despite these enticing advantages, a major problem limit-
ing development of peptide therapeutics is their proteolytic
sensitivity and associated delivery challenges. Synthetic thera-
peutic peptides are typically relatively unstructured and are
therefore rapidly degraded in vivo, often with half-lives on
the order of minutes.1 Proteolysis commonly occurs in the
GI lumen, intestinal brush border, enterocytes, hepatocytes,
antigen-presenting cells, and plasma. Because of this in vivo
fragility, oral delivery is generally not possible, necessitating
frequent dosing by injection. Even when delivered parenter-
ally, degradation in the blood combined with rapid renal fil-
tration often results in drugs that are expensive, inconven-
ient, and unpleasant to administer.
Protease-resistant peptides would address many of these
limitations. One of the most promising approaches is to
modify the chemical structure of the peptide backbone (pep-
tidomimetics).2 Modifications that have been shown to sub-
stantially decrease proteolysis include N-methylation, ester
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ABSTRACT:
Peptides have great potential as therapeutic agents, but
their use is often limited by susceptibility to proteolysis and
their resulting in vivo fragility. In this review, we focus on
peptidomimetic approaches to produce protease-resistant
peptides with the potential for greatly improved clinical
utility. We focus on the use of mirror-image (D-peptide)
and ß-peptides as two leading approaches with distinct
design principles and challenges. Application to the
important and difficult problem of inhibiting HIVentry
illustrates the current state-of-the-art in peptidomimetic
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linkages (a-hydroxy acids), insertion of additional methylene
groups into the backbone (b-amino acids, c-amino acids
etc.), and the use of D-amino acids. More significant changes
to the peptide backbone include peptoids, azapeptides,
oligoureas, arylamides, and oligohydrazides.2–4
In this review, we describe how modified peptide back-
bones can be used to design protease-resistant inhibitors
with a special focus on the high-priority problem of design-
ing protease-resistant HIV entry inhibitors. Although these
modified backbones effectively address protease sensitivity,
each is associated with a set of design challenges using
rational design or library screening techniques. This review
will not cover traditional strategies to reduce protease sensi-
tivity, e.g., peptide capping, sequence alteration at susceptible
sites, cyclization, or stapling, which have been extensively
reviewed elsewhere.5
INHIBITING HIV ENTRY
An estimated 34 million people worldwide are infected with
HIV, the causative agent of AIDS, resulting in nearly 2 mil-
lion deaths per year and over 25 million cumulative deaths
(UNAIDS). Dramatic progress has been made in reducing
mortality since the inception of antiretroviral therapy against
HIV enzymes reverse transcriptase, protease, and recently
integrase. However, the relentless development of drug resist-
ance necessitates ongoing development of therapeutics that
target other stages in the viral lifecycle. In particular, there
have been extensive efforts to develop potent, broadly active,
and economical entry inhibitors for the prevention and treat-
ment of HIV/AIDS.6
The current HIVentry pathway model is shown in Figure 1.
Viral entry into host cells is mediated by the trimeric HIV en-
velope (Env) glycoprotein. Env contains the noncovalently
associated surface gp120 and transmembrane gp41 subunits.
gp120’s primary function is to interact with cell receptors that
mark HIV’s preferred target cells (e.g., T-cells and macro-
phages), while gp41 induces membrane fusion. Host cell inter-
actions are mediated by gp120 through association with the
primary cell receptor (CD4) and chemokine coreceptor (either
CXCR4 or CCR5, depending on viral tropism). Upon gp120
engagement with cell receptors, a complex series of structural
rearrangements in gp120 propagate to gp41, activating it for
membrane fusion (reviewed by Ref. 7). At this stage, gp41
forms an extended prehairpin intermediate containing an
N-terminal trimeric coiled coil (N-trimer) and C-terminal
region (C-peptides) of unknown structure. Fusion is driven by
collapse of this intermediate as three helical C-peptides pack
anti-parallel to the N-trimer (trimer-of-hairpins formation),
drawing the viral and host cell membranes into close proximity.
A similar fusion mechanism is utilized by many other enveloped
viruses, including influenza, Ebola, and paramyxoviruses.7
C-Peptide Inhibitors
This mechanism suggests that peptides derived from the
N- and C-peptide regions of gp41 could prevent viral mem-
brane fusion in a dominant-negative manner by preventing
trimer-of-hairpins formation. Indeed, both N-and C-pep-
tides inhibit HIV entry.8–14 The N-trimer/C-peptide interac-
tion is predominantly mediated by conserved interactions
between the hydrophobic face of helical C-peptides and a
hydrophobic groove formed between helices in the N-trimer.
C-peptide inhibitors are more promising drug candidates
because of their higher potency and better solubility com-
pared with N-peptide inhibitors.
C-peptide inhibitors were first identified through screens
of gp41-derived peptides.9,11 Fuzeon (Enfuvirtide, T-20) is a
36 amino acid L-peptide taken from the gp41 C-peptide
region. Fuzeon inhibits HIV entry with nM potency and
reduces viral loads by 2 logs,15 leading to its approval as the
first HIV entry inhibitor in 2003. Unfortunately, Fuzeon’s
clinical use has been limited by its short half-life. Fuzeon
requires injection at very high doses (90 mg, twice daily) to
overcome its proteolysis and rapid renal filtration. These
practical problems result in a drug that is expensive
(*$30,000 per year), can cause painful injection site reac-
tions, and is only approved for patients experiencing treat-
FIGURE 1 HIV entry pathway. HIV Env is composed of surface
(gp120, green) and transmembrane (gp41, blue) subunits. Fusion is
initiated by binding to CD4 and a chemokine coreceptor, which
activates gp41 and induces formation of the prehairpin intermedi-
ate. In this intermediate, the gp41 N-terminal region forms a tri-
meric coiled coil (N-trimer, gray), which is separated from the C-
peptide region (dark blue). This intermediate slowly collapses to
form a trimer-of-hairpins structure that brings the viral and cell
membranes into close apposition, leading to fusion. C-peptide and
D-peptide inhibitors bind to the N-trimer, preventing trimer-of-
hairpins formation and membrane fusion.
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ment failure due to multi-drug resistance (‘‘salvage therapy’’).
Fuzeon’s high dosing requirements and in vivo fragility also
limit options for less frequent dosing via depot formulation.
The gp41 ‘‘Pocket’’ Region
At the N-trimer’s C-terminus lie three symmetry-related
deep hydrophobic pockets. Each pocket has a volume of
*400 A˚3 that is filled primarily by three C-peptide residues
(Trp628, Trp631, and Ile635)16,17 (Figure 2). The pocket is a
promising inhibitory target because of its critical importance
in membrane fusion and very high level of conservation
across diverse HIV strains.16,18 Mutations in the pocket are
often not well tolerated due to the requirement for compen-
satory mutations in the C-peptide region to restore binding.
In addition, the pocket region is encoded by the structured
RNA region of the Rev-responsive element (RRE), which
contains a signal critical for nuclear export of viral RNA.18
Interestingly, extensive efforts by numerous groups to dis-
cover small molecule pocket-binding inhibitors have had
limited success, generally producing inhibitors with modest
potency and/or significant toxicity.19–23 Based on this body
of work, the gp41 pocket appears to be ‘‘undruggable’’ by
small molecule inhibitors, a common problem for extended
protein–protein interaction interfaces.
Fuzeon was discovered before the gp41 6-helix bundle
crystal structure and does not bind to the gp41 pocket. How-
ever, next generation C-peptide inhibitors (e.g., C34, T-1249)
do include pocket-binding residues and enjoy superior
potencies and resistance profiles.24–26 The follow-on com-
pound to Fuzeon, T-1249, performed very well in clinical tri-
als, but was not developed further due to unspecified formu-
lation problems, which we speculate includes challenges in
the economic synthesis of this 39-residue peptide and a
requirement for four 1 mL injections, once per day, as used
in a phase I/II trial.25
Fuzeon and T-1249 show that a peptide fusion inhibitor
can be very effective against HIV, but the impact of such
drugs will be limited until the problems of short half-life and
high dosing (and the resulting high cost) can be overcome.
In this review, we focus on two distinct strategies that have
yielded promising protease-resistant peptide fusion inhibi-
tors with the potential to overcome Fuzeon’s in vivo fragility.
RATIONAL DRUG DESIGN WITH MODIFIED
PEPTIDE BACKBONES
While there is much interest in the de novo development of
peptides with defined structural and functional characteris-
tics, this work is hampered by limitations in currently avail-
able modeling strategies. Thus, as illustrated below, most suc-
cessful rational designs of protease-resistant peptides start
from sequence and structural information from existing pep-
tide ligands.
In the realm of rational design of modified peptide thera-
peutics, b-peptides and mixed a/b-peptides are among the
most promising. b-peptides are composed of b-amino acids,
which contain an extra backbone methylene group (between
FIGURE 2 One pocket, two binding solutions. The gp41 pocket (from pdb code 3L35) is shown
with (A) the natural gp41 C-peptide (pdb code 1AIK) and (B) D-peptide PIE12 (pdb code 3L35).
Structures were aligned on the 17 pocket-forming residues from gp41 and rendered using Pymol.
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the amino and a-carbon, specified as a b2-amino acid, or
between the carboxylate and a-carbon, specified as a
b3-amino acid) (Figure 3). Short b-peptide sequences can
adopt robust secondary structures analogous to a-helices
formed by a-amino acids. If a natural helical peptide ligand
is known, a b-peptide mimic can be generated by the precise
placement in three dimensions of key side chains onto a
b-peptide scaffold. Two b-peptide scaffolds that have been
extensively utilized are the 12-helix and 14-helix, named after
the number of atoms between hydrogen bonding groups
(these and other b-residue-containing scaffolds are reviewed
elsewhere3,27–30). The specific structural motif adopted by a
particular b-peptide is dictated by the nature of the substitu-
ent b-amino acids.31 b-peptides composed of monosubsti-
tuted, acyclic b-amino acids or cyclic six-member ring
b-amino acids preferentially adopt the 14-helix structure,
while the 12-helix structure is favored by peptides composed
of cyclic five-member ring b-amino acids. The helical param-
eters of the 12- and 14-helices are discussed and compared
with a-helices in Refs. 27 and 31.
In a 14-helix composed of b3-amino acids, side chains at
residues i, i+3, and i+6 are presented along the same face of
the helix, and are reasonably superimposable with side chains
at residues i, i+4, and i+7 of an a-helix.32 This property can
be exploited to display epitopes that mimic an a-helical face
and has been applied to the development of low-mid lM
HIV entry inhibitors that bind to the gp41 pocket region.33,34
In an analogous approach, b-peptide inhibitors of HCMV
entry were developed using the 12-helix scaffold.35 To map
an a-helix epitope onto the 12-helix, side chains at positions
i, i+4, and i+7 on the a-helix are placed at positions i, i+3,
and i+5 on the 12-helix. Although acyclic residues diminish
12-helix propensity, they provide the easiest avenue for side
chain attachment, so a minimum number of acyclic b2 or b3
residues were introduced into the structure at specific points
to mimic side chain presentation of the native a-helix. This
approach enabled the rapid discovery of inhibitors with
modest potency, but its main challenge is the lack of a route
forward, by rational design or high-throughput screening, to
optimize these initial hits.
A sequence-based approach utilizing mixed a/b-peptides
has been applied to develop an HIV entry inhibitor that
structurally and functionally mimics C-peptides (*10 turn
a-helix).36 In this approach, a subset of C-peptide residues
were strategically replaced with homologous b3-amino acids
following an aabaaab pattern, which, despite the additional
methylene units, does not significantly alter secondary struc-
ture of the helix.37 On folding, this pattern generates an a-
helix-like conformation with a b-residue stripe that runs
down the side of the helix distal to the interaction surface,
minimizing disruption of the binding interface. On replacing
11 of the 38 residues with b3-amino acids, the resulting a/b-
peptide had >10,000-fold diminished affinity for its binding
target relative to the a-peptide counterpart.
As a second step in the design, specific b3-residues were
replaced by cyclic b-residue homologues. The cyclic residues
were incorporated to reduce the entropic penalty associated
with helix formation due to the inherent torsional flexibility
of b3-residues. b3 analogues of alanine in the a/b-peptide
were replaced with a nonpolar, five-member ring constrained
b-residue (ACPC), while b3 analogues of arginine were
replaced with a polar, heterocyclic analogue of ACPC (APC).
These replacements improved affinity by*400-fold over the
peptide with acyclic residues. Although the binding affinity
never recovers to that of the original a-peptide ligand, the
resulting a/b-peptide was nearly as potent as the a-peptide,
but with the added advantage of being 280-fold more resist-
ant to proteolytic degradation by proteinase K. The apparent
discrepancy of having diminished binding affinity, yet a-pep-
tide-like potency is likely due to the potency plateau
observed for many HIV entry inhibitors (see the discussion
of the ‘‘resistance capacitor’’ below).
The original report indicated that the N-terminal Trp-
Trp-Ile motif of the a/b-peptide does not engage the C-ter-
minal hydrophobic pocket of gp41, but subsequent crystallo-
graphic analysis indicated that that the pocket-binding motif
FIGURE 3 Peptidomimetic structures.
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on the a/b-peptide is indeed able to engage the pocket. The
authors suggest that the lack of engagement in the original
structure was an artifact caused by crystal packing, and that
the newer structure more faithfully portrays the binding of
the a/b-peptide (see discussion in supplementary materials
of Ref. 38).
GENETICALLY ENCODED LIBRARY-BASED
SCREENS
An alternative to rational design is screening of random pep-
tide libraries. These high-throughput methods identify novel
peptides with a desired function (typically binding to an im-
mobilized target). Commonly used screening techniques
include phage, ribosome, and mRNA display, but these
methods all rely on cellular translation machinery and are
therefore not yet fully compatible with peptidomimetics in
their standard forms. Though there have been many advan-
ces and refinements in the field of synthetic peptidomimetic
library generation (e.g., split and pool synthesis, physically
addressable synthesis by photolithography), these synthetic
libraries are typically limited to <106 members39 compared
with the billion to trillion member libraries that can be gen-
erated with genetically encoded libraries.
D-Peptides
D-peptides are entirely composed of D-amino acids, which
are mirror-image stereoisomers of the L-amino acids found
in naturally occurring L-peptides. D-Peptides are a promising
therapeutic platform because they are highly resistant to nat-
ural proteases.40 In elegant work by the Kent group,41 D-HIV
protease was shown to cleave only D-peptide substrates,
showing that proteases exhibit highly stereospecific substrate
discrimination.
The symmetry relationship between L- and D-peptides can
be exploited in mirror-image display techniques42 in which a
mirror-image version of the target molecule is generated by
solid-phase synthesis using D-amino acids. Randomized ge-
netically encoded L-peptide libraries are then screened against
this D-target. The winning L-peptides are identified by DNA
sequencing and then the corresponding D-peptides are syn-
thesized. By symmetry, the D-peptide will have the same ac-
tivity toward the natural L-target as the L-peptide had against
the mirror-image D-target (Figure 4).
A major limitation of mirror-image display is the require-
ment for chemical synthesis of the D-target. Synthesis of D-
peptides is currently done using traditional solid phase pep-
tide synthesis (SPPS).43 Routine use of SPPS chemistries for
the production of peptides is limited to *50 residues,
though this limit varies widely depending on the required
purity and sequence/structure properties of the peptide in
question (e.g., extended beta-strand peptides can aggregate
during SPPS). Despite these challenges, syntheses of very
long peptides have been reported (e.g., the synthesis of the
140-residue IL-3 protein44).
Larger D-peptide targets can be obtained using peptide li-
gation techniques to link multiple synthesized peptide frag-
ments. A variety of ligation chemistries have been developed
(see Ref. 45 for a very thorough review), but the most com-
mon technique is cysteine-mediated native chemical ligation
(NCL). NCL requires the presence of an N-terminal cysteine
on one peptide fragment and a C-terminal thioester on the
other (see Ref. 46 for a summary of popular recombinant
and synthetic methods for the generation of peptides bearing
a C-terminal thioester) and results in the ligation of the two
segments via a native peptide bond. SPPS of thioester-con-
taining peptides has traditionally been carried out via Boc
chemistry, but recent advances have enabled the robust syn-
thesis of thioesters using the easier and more popular Fmoc
chemistry47 and commercially available Dawson Dbz resin
(Novabiochem). Other means of accessing peptide thioesters
via Fmoc chemistry have been recently reviewed.48
By strategically utilizing masked N-terminal cysteines
(e.g., thioproline), multiple peptide fragments can be joined
together sequentially or in a single-pot reaction.49–53 This
strategy has been used in the D-peptide synthesis of the 81-
residue snow flea antifreeze protein.54 NCL leaves a Cys resi-
due at each ligation site, but this ‘‘scar’’ can be removed by
desulphurization of the cysteine residue to alanine.55,56 Fur-
thermore, several creative adaptions of NCL allow residues
other than an N-terminal cysteine to be present at the liga-
FIGURE 4 Mirror-image phage display. Phage bearing L-peptides
are panned against a mirror-image protein (D-target). By symmetry,
D-versions of binding peptides will bind to the natural L-targets.
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tion junction, such as N-terminal, thiol-containing auxiliary
groups that can be removed via reduction,57 UV irradia-
tion,58,59 or treatment with acid60,61 after they have facilitated
peptide bond formation. In another approach, modified ver-
sions of phenylalanine,62 valine,63 or lysine64 bearing a thiol
substituent were incorporated at the N-terminus of a peptide
fragment and yielded the respective native amino acid at the
ligation site following NCL/desulfurization.
Once a D-target has been synthesized, it can be used in
conjunction with mirror-image display to screen peptide
libraries for novel sequences of interest (see our work on
HIV below and Ref. 65). The unifying feature that underlies
all of the library-based display techniques discussed here is
the physical linkage of a peptide to its corresponding geno-
type (RNA or DNA). This linkage allows the library to be
subjected to multiple rounds of interrogation/library amplifi-
cation leading to enrichment of sequences that bind to a tar-
get of interest. In these techniques, library diversity is gener-
ated in the nucleotide coding sequence, and cellular machin-
ery efficiently translates this information into a peptide
library. The display techniques most suitable for screening
high-diversity libraries can be broken down into two broad
categories: viral display and cell-free display systems
(briefly described here, but for a more extensive review see
Refs. 66–70).
Viral Display
Phage display continues to be the workhorse of the viral dis-
play techniques because of its ease of use, versatility, and low
cost. Since phage display requires a bacterial transformation
step, library size is typically limited to *109–1010. The most
commonly utilized phage display system is the nonlytic M13-
family filamentous phage, in which the peptide library is
expressed as an N-terminal fusion with the pIII minor coat
protein. Up to five copies of pIII are present on the phage
surface, making both polyvalent and monovalent display
techniques possible. Polyvalent display provides a strong
avidity effect, which is highly advantageous for screening na-
ı¨ve peptide libraries containing only rare low affinity binders.
In contrast, monovalent display reduces avidity and allows
for more stringent selection of peptides with high affinity. In
an early round of phage display, library diversity is high, but
each sequence is represented by only a few phage. As with
any library display method, the application of selection pres-
sure must be sufficient to drive selection for tighter binders,
but not so severe as to eliminate rare tight binding sequences
due to stochastic factors. In later rounds, as phage library di-
versity drops and each remaining sequence is represented by
numerous phage, selection pressure can be steadily increased.
Insufficient selection pressure can select for ‘‘cheater’’ phage
that do not bear authentic tight binding peptides (e.g., phage
with growth advantages).
Besides filamentous phage display, techniques employing
various eukaryotic viruses, including retroviruses, baculovi-
rus, Adeno-associated virus, and Adenovirus have been or
are currently being developed for displaying peptide libra-
ries.67 Other display techniques (e.g., bacterial, yeast, or
mammalian cell display) have several advantages over phage
display (e.g., more sophisticated folding machinery, post-
translational modifications, ability to use FACS sorting), but
are more complex and typically limited to less diverse libra-
ries (reviewed by Refs. 66, 67, 71, 72).
Cell-Free Display
One of the major advantages of cell-free techniques (reviewed
by Ref. 73) is that they are carried out in vitro. Because a
transformation step is not required, library diversities >1012
can be generated.69 Due to the proposed correlation between
library diversity and the affinity of selected ligands, this large
increase in library diversity over typical viral or cell surface
display systems provides a distinct advantage.
Ribosome display74,75 capitalizes on the fact that it is pos-
sible to stall the in vitro translation of a polypeptide so that
the ribosome remains assembled and attached to the mRNA
transcript and the nascent translated polypeptide. This
mRNA-ribosome-polypeptide ternary complex serves to link
genotype to phenotype and can be panned against a target to
isolate sequences of interest. The ternary complex can then
be eluted and dissociated with EDTA, allowing for the isola-
tion of the original mRNA transcript.
Alternatively, RNA display76 links phenotype to genotype
by connecting an mRNA sequence directly to the peptide it
encodes. This linkage is accomplished by chemically attach-
ing the antibiotic puromycin to the 3’ end of the RNA via a
DNA linker. As the mRNA is being translated, the ribosome
will stall once it reaches the DNA linker, allowing puromycin
to enter the ribosomal A site, where the ribosome catalyzes
covalent attachment to the recently translated polypeptide.
This peptide–RNA complex can then be subjected to panning
against a specific target.
While in vitro display techniques that link the peptide
phenotype to an RNA genotype overcome many of the limi-
tations of phage display, the instability of RNA molecules
along with other technical challenges fundamental to these
techniques has limited their application to a relatively small
number of expert laboratories. To address these challenges,
techniques that link the library peptides directly to their
encoding DNA have recently been developed.
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CIS display (Isogenica) exploits the unique activity of
RepA, a bacterial plasmid DNA-replication initiation pro-
tein.77 RepA is a cis-acting protein that tightly binds to the
origin of replication (ori) on the plasmid from which it was
expressed. A stretch of DNA between the sequence that enco-
des RepA and the ori known as the CIS element contains a
rho-dependent transcriptional terminator that is thought to
stall the RNA polymerase during transcription of RepA. The
current model holds that this delay allows the newly synthe-
sized RepA protein emerging from the ribosome to interact
with the CIS element, which subsequently directs RepA to
the ori DNA. Peptide libraries can be fused to the N-terminus
of RepA, thereby creating a link between phenotype and the
DNA genotype. Like other in vitro techniques, CIS display
has the capability to accommodate peptide libraries much
larger than those possible for phage display. In one exam-
ple,77 a library of >1012 randomized 18-mer peptides was
constructed and was used to isolate sequences that bound to
disparate targets. In a similar approach, DNA sequences
encoding randomized peptide libraries are fused to the bacte-
riophage P2A gene. P2A is an endonuclease involved in the
rolling circle replication of bacteriophage P2 DNA. P2A
becomes covalently attached to the same DNA molecule
from which it was expressed, linking phenotype to genotype.
This technique has been used in a pilot study to select single-
chain antibodies from a 107-member library and may be suit-
able for screening much larger libraries.78
D-PEPTIDE INHIBITORS OF HIV ENTRY
Here we describe the history of our potent D-peptide inhibi-
tors of HIVentry, developed in the Kim and Kay laboratories.
Initially, mirror-image polyvalent phage display was used to
screen naı¨ve peptide libraries of various lengths and geome-
tries for binding to an HIV N-trimer pocket mimic
(IQN17).18 Pocket-specific binding was only observed in di-
sulfide-constrained 10-mer sequences (CX10C) containing an
EWXWL consensus sequence. An initial group of *10 win-
ning sequences were validated by measuring their binding to
the desired target and several negative control targets
(mutated or missing pockets) to demonstrate pocket-specific
binding.
Validated D-peptides inhibited HIV entry (lab strain
HXB2) with IC50 values ranging from 11 to 270 lM.
18 A co-
crystal structure of one of the higher affinity D-peptides
(D10-p1) in complex with IQN17 shows that D10-p1 con-
tains two short left handed a-helical segments flanking a turn
imposed by the disulfide constraint. The binding interface
between the hydrophobic pocket of IQN17 and D10-p1 is
mediated by residues in the C-terminal a-helix, with residues
in the EWXWL consensus motif making the largest contribu-
tions. Comparison of the D10-p1/IQN17 crystal structure to
the native post-fusion gp41 structure17 reveals that critical
residues for binding in D10-p1 are very similar in chemical
character to those of the natural C-peptide ligand (primarily
W628, W631, and I635), but adopt distinct conformations
due to their opposite chirality.
Due to library diversity limitations, the first-generation
library only surveyed about one in a million possible sequen-
ces.18 The identification of a strong EWXWL consensus
sequence allowed us to fix these four residues to produce a
‘‘constrained’’ library with only six randomized residues
(*109 possible sequences). Panning this library produced
*4-fold more potent inhibitors.79
Surprisingly, an 8-mer (CX8C) was also among the win-
ning sequences. Since 8-mers were not part of the library
design and likely arose from rare replication errors, their rel-
ative success suggested that the 8-mer geometry might pro-
vide a better pocket-binding solution. Our crystal structure
of the first identified 8-mer, PIE1 (pocket-specific inhibitor
of entry), bound to IQN17 reveals that the key pocket-bind-
ing residues (WXWL) adopt nearly identical positions within
the pocket as seen with D10-p1, leading to very similar bind-
ing interfaces despite PIE1’s reduced length.79 The key differ-
ence between PIE1 and D10-p1 is a more compact D-peptide
structure with a tighter hydrophobic core devoid of water.
PIE1 has a D-Pro at position 8 that likely aids making the
tighter turn necessary for circularization forced by the
shorter disulfide-constrained loop.79
To completely explore 8-mer sequence space, a new library
was generated with the core consensus sequence WXWL
fixed (CX4WXWLC). While screening this library using tra-
ditional solid-phase phage display, we observed that polyva-
lency made it difficult to distinguish modest (lM) and tight
(nM) binders. Solid-phase target presentation is advanta-
geous for selection of weak initial binders from a naı¨ve
library, but problematic for identifying strong binders in a
sea of modest binders since all binders are strongly retained
on the high-density target surface. Moving the binding reac-
tion into solution (solution-phase phage display) reduces
inter-target avidity and allows additional selection pressure
by reducing target concentration through rounds of pan-
ning.80 Despite reduced inter-molecular avidity, solution-
phase phage were still found to have dramatically higher
binding affinities in the context of the panning than expected
based on KD values of the derived D-peptides, likely due to
intra-molecular avidity on the trimeric target. To overcome
this barrier, an L-peptide version of PIE279 (identified during
earlier rounds of solution-phase phage display) was
employed as a soluble competitor for subsequent rounds of
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panning. Increased selection pressure was applied by escalat-
ing PIE2 concentrations, leading to the discovery of PIE7,
which is *15-fold more potent than D10-p1 (IC50 ¼ 620
nM, HXB2 strain).
Our co-crystal structure of PIE7 in complex with IQN17
suggested that further gains in binding affinity could be
made through optimization of the residues outside the disul-
fide bond, which make significant gp41 contacts.79 Initially,
these four ‘‘flanking’’ residues outside the disulfide bond
(Gly–Ala on the N-terminus and Ala–Ala on the C-termi-
nus) were not varied due to library cloning restrictions. We
redesigned the phage display vector to relocate the cloning
sites and allow randomization of the flank residues. After
four rounds, PIE12 (HP-[PIE7 core]-EL) was identified with
*20-fold improved potency over PIE7. The PIE12/IQN17
crystal structure (Figure 2) reveals that PIE12’s improved
binding is likely due to ring-stacking interactions of D-His1
and D-Pro2 with the pocket residue Trp571 and burial of an
additional 50 A˚2 hydrophobic of surface area by D-Leu15.81
Beyond the changes in the flanking regions, the central core
structure is unchanged from PIE7.
Crosslinking and the Resistance Capacitor
After battling the confounding effects of avidity throughout
our phage display screens, we hoped to re-introduce avidity
to boost the potency of our D-peptides. Our D-peptide/N-
trimer crystal structures reveal the precise relationship
between neighboring D-peptides binding to the three symme-
try-related pockets. Using this information, we used discrete
polyethylene glycol (PEG) crosslinkers to generate dimeric
and trimeric D-peptides,79 which showed dramatically
improved antiviral potency (up to 2000-fold) over mono-
meric D-peptides.79,81 PIE12-trimer, our lead inhibitor, is
*30-fold more potent than Fuzeon and inhibits a diverse
panel of the most common circulating HIV strain subtypes
worldwide in the high pM—low nM range.81
Interestingly, we encountered a limit to the potency gains
that could be achieved by monomer affinity optimization
and crosslinking. We hypothesized that this potency plateau
was imposed by the limited time window available for inhibi-
tor binding (target is only available in the transient pre-hair-
pin intermediate) and the inhibitor association rate (limited
by diffusion), as previously observed for the pre-hairpin in-
termediate inhibitor 5-helix.82 Although this potency limit
would prevent us from designing more potent inhibitors, we
hypothesized that ‘‘over-engineering’’ our inhibitors (i.e.,
continuing to improve inhibitor binding despite a lack of
corresponding improvement in potency) would endow them
with a reserve of binding energy that would stall the develop-
ment of resistance mutations. We predict that this ‘‘resistance
capacitor’’ would also greatly delay the emergence of resist-
ance by eliminating the selective advantage conferred by
these mutations (i.e., severing the link between affinity and
potency). Only a profoundly disruptive mutation would
escape the resistance capacitor. In support of this hypothesis,
we were only able to identify high-level PIE12-trimer resist-
ance after 65 weeks of viral passaging in the presence of in-
hibitor, compared with*3 weeks for Fuzeon.81 As predicted,
PIE12-trimer was also able to absorb the impact of earlier-
generation D-peptide resistance mutations.
PROTEASE-RESISTANT PEPTIDES FACE
OTHER PHARMACOKINETIC CHALLENGES
Reduction of peptide susceptibility to proteases increases pep-
tide longevity, but another major threat to serum half-life is
rapid clearance via renal filtration. For globular proteins, the
glomerular filtration size limit is*70 kDa. Although albumin
is slightly smaller, it avoids filtration because of electrostatic
repulsion from the highly negatively charged glomerular base-
ment membrane. Albumin is the smallest major unfiltered
protein, efficiently circulating in the bloodstream with a half-
life of approximately 19 days in humans.83 The small size of
peptide therapeutics means that an additional level of design
is required to reduce renal filtration and realize the full bene-
fits of protease resistance. Several common PK optimization
strategies suitable for peptides are briefly described below.
PEG is a hydrophilic polymer commonly used for protein
conjugation. Adding PEG to a protein has been one of the
most clinically successful strategies for improving pharmaco-
kinetics.84 Early studies on the effects of PEG size on biodis-
tribution revealed that good serum retention is achieved
between 40 and 60 kDa, while exceeding this range resulted
in increased uptake and accumulation within the reticuloen-
dothelial system.85 Thus, the PEGylation field has largely
adopted the strategy of adding *40 kDa of PEG weight to
peptide and small protein therapeutics. PEG is extensively
hydrated such that its hydrodynamic radius is much larger
than expected from its molecular weight. Furthermore, dis-
tributing the weight of the PEG polymer in a branched ge-
ometry improves half-life and reduces steric interference.86
PEG conjugation can also be reversible (e.g., an ester link-
age), creating a circulating depot from which the therapeutic
is cleaved over time (e.g., in case drug activity is adversely
affected by PEG conjugation).87,88 Limitations of PEGylation
include steric interference with binding, long-lived accumu-
lation in renal tubule cells, viscosity, and polydispersity. An
alternative approach uses a hydroxyethyl starch polymer
(HESylation) to reduce renal filtration.89
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Albumin binding (covalent or noncovalent) is another
recently validated approach for prolonging serum half-life
(reviewed by Ref. 90). Promising albumin-binding strategies
include covalent albumin-peptide conjugation, as well as re-
versible binding to circulating albumin via albumin-binding
peptides, small molecules, or fatty acids.90–92 As an example,
albumin conjugation of an HIV C-peptide inhibitor (either
in vitro or in vivo) dramatically improves serum half-life,93 as
does cholesterol conjugation to a lesser extent, presumably
via weak reversible interactions with albumin and/or cell
membranes.94
FUTURE DIRECTIONS
Recombinant Production of Peptidomimetics
Although robust recombinant production of peptidomimet-
ics is not yet possible, significant recent advances in synthetic
biology may enable routine production of diverse peptidomi-
metic libraries in the near future. One promising approach is
in vitro codon reprogramming for the synthesis of unnatural
polymers. This approach relies on cell-free translation sys-
tems to reconstitute ribosomal peptide synthesis using a
minimal set of purified protein components.95–100 By chemi-
cally or enzymatically charging tRNA molecules with novel
amino acid analogues, the genetic code can be effectively
reprogrammed in vitro. When these cell-free systems with
genetic code modifications are used in conjunction with a
display technology, peptides with novel amino acids can be
screened for a desired property. For example, ribosome dis-
play was used in conjunction with in vitro codon reprogram-
ming to isolate peptide sequences from an mRNA library
that encoded an unnatural, selectable amino acid.101–103
Along these lines, it has been demonstrated that tRNAs
can be charged with a variety of amino acid analogues that
will modify the peptide backbone, including a-hydroxy acids,
N-methyl amino acids, a,a-disubstituted amino acids,
b-amino acids, and D-amino acids.104 However, the efficiency
of ribosomal incorporation of Ala/Phe analogues varies
greatly from fairly robust (a-hydroxy acid and N-methyl) to
weak (a,a-disubstituted amino acids) to undetectable (b- and
D-amino acids).104 Subsequent work has described the ability
of the translation machinery to accommodate amino acid
analogues with novel side chains and backbones.105
In one example, seven codons were each reassigned to
encode a unique a-hydroxy acid, and polymers as long as 12
consecutive a-hydroxy acids could be synthesized.106 In
another report, the incorporation efficiencies of 23 N-methyl
amino acids, 19 of which bore naturally occurring side
chains, were determined. Eight of these 19 N-methyl amino
acids were incorporated at specific points in a polypeptide
with >30% efficiency as compared with wild type. A peptide
up to 10 residues long could be synthesized from three
unique N-methyl amino acids.107
While less success has been reported with ribosomal
incorporation of D-amino acids, modifications to the ribo-
somal peptidyltransferase center and helix 89 of the 23S
rRNA can relax the ribosome’s natural substrate specificity,
thereby enhancing the incorporation of D-amino acid resi-
dues into a growing polypeptide chain.108,109 Although these
techniques have not yet been employed as such, in principle
cell-free translation systems coupled with in vitro display
techniques could be used to screen libraries of polymers with
novel backbones. As an advance in this direction, genetic
code reprogramming has already been used in conjunction
with mRNA display technology to generate mRNA-peptide
fusions containing N-methyl amino acids.110
Another approach to recombinantly produce peptidomi-
metics relies on the ability to expand the genetic code in vivo
via the generation of evolved tRNA/aminoacyl-tRNA synthe-
tase pairs. In these systems, the foreign tRNA functions as an
amber suppressor, effectively allowing the amber nonsense
codon to be reprogrammed to encode a non-natural amino
acid.111,112 It has been demonstrated that genetic code expan-
sion can be used in conjunction with phage display to incor-
porate a non-natural amino acid into a pIII fusion pep-
tide.113 In the future, multiple codons could be reassigned,
permitting the incorporation of multiple unnatural residues
in vivo. Several advances have been made toward this end. In
a recent publication describing a technique for rapid, ge-
nome-wide engineering, the authors show progress toward
replacing all 314 TAG stop codons in E. coli with the TAA
stop codon.114 This type of genome manipulation could be
used for the removal of redundancy from the genetic code,
freeing up codons for potential reprogramming. In another
approach involving evolved tRNA/aminoacyl-tRNA synthe-
tase pairs, an evolved orthogonal ribosome able to read both
3- and 4-base codons was able to efficiently incorporate two
different non-natural amino acids into a single polypeptide
chain in vivo.115,116 These approaches present tantalizing pos-
sibilities for the production of peptide libraries with unnatu-
ral side chains and backbones, but the technology is not yet
sufficiently robust to allow for widespread application. Addi-
tional engineering of tRNA molecules, elongation factors,
and the ribosome itself will likely be required for use with
certain diverse peptidomimetics.109,117,118
D-Peptides present a unique opportunity for designing an
artificial recombinant production system. Because of their
symmetry relationship with natural peptides, an in vitro
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translation system composed of all opposite-chirality compo-
nents (D-proteins and nucleotides containing L-ribose) would
function equivalently to natural translation, when provided
with mirror-image DNA substrates. Synthesis of all ribo-
somal components presents an enormous synthetic chal-
lenge, but recent advances in SPPS and peptide ligation may
now make this approach feasible. A mirror-image in vitro
translation system would provide a useful tool for D-peptide
drug discovery and production, but may not be ideal for
large-scale production, especially of complex D-proteins (e.g.,
those requiring chaperones or post-translational modifica-
tions). The ultimate goal is to produce D-peptides using a
synthetic mirror-image organism, a strategy we dub the ‘‘D.
coli’’ project. The key to this project is synthesizing the mini-
mal set of RNAs and proteins necessary to allow enzymatic
production of other larger components and ultimately all
components needed for a self-replicating organism. It is also
not yet clear how to ‘‘start up’’ such an organism.119,120
Cost and Toxicity of Peptidomimetics
In addition to achieving their biological objectives, peptido-
mimetics will need to overcome concerns about cost and tox-
icity to succeed as therapeutics. Currently there are no FDA-
approved fully peptidomimetic peptides, so information on
their in vivo toxicity is extremely limited. Initial data from
two D-peptides that have advanced to clinical trials (Gen-
zyme’s Delmitide121 and Allelix’s ALX40-4C122) showed that
both D-peptides (one orally administered, one systemically
delivered) were well tolerated in humans. Further comfort is
provided by over a dozen approved D-amino acid-containing
peptides, as well as two approved ß-amino acid-containing
peptides.123 These data suggest that these amino acids are
not intrinsically toxic, but more rigorous animal toxicology
studies on different classes of fully protease-resistant peptides
will be required for a definitive determination. Such studies
will also determine whether these peptidomimetics induce
significant immunogenicity upon chronic administration.
Finally, the cost of D-, b-, and other uncommon amino acids
is currently significantly higher than the corresponding com-
mon L-amino acids, largely because of their current status as
specialty reagents. However, we anticipate the cost of these
amino acids will drop dramatically as they are adopted in
high-volume production of therapeutic peptides, as has al-
ready occurred with several D-amino acids in large-scale pep-
tide production.
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The HIV gp41 N-trimer pocket region is an ideal viral target because it is extracellular, highly conserved, and
essential for viral entry. Here, we report on the design of a pocket-specific D-peptide, PIE12-trimer, that is
extraordinarily elusive to resistance and characterize its inhibitory and structural properties. D-Peptides
(peptides composed of D-amino acids) are promising therapeutic agents due to their insensitivity to protease
degradation. PIE12-trimer was designed using structure-guided mirror-image phage display and linker opti-
mization and is the first D-peptide HIV entry inhibitor with the breadth and potency required for clinical use.
PIE12-trimer has an ultrahigh affinity for the gp41 pocket, providing it with a reserve of binding energy
(resistance capacitor) that yields a dramatically improved resistance profile compared to those of other fusion
inhibitors. These results demonstrate that the gp41 pocket is an ideal drug target and establish PIE12-trimer
as a leading anti-HIV antiviral candidate.
The HIV envelope protein (Env) mediates viral entry into
cells (11). Env is cleaved into surface (gp120) and transmem-
brane (gp41) subunits that remain noncovalently associated to
form trimeric spikes on the virion surface (16). gp120 recog-
nizes target cells by interacting with cellular receptors, while
gp41 mediates membrane fusion. Peptides derived from hep-
tad repeats near the N and C termini of the gp41 ectodomain
(N and C peptides) interact in solution to form a six-helix
bundle, representing the postfusion structure (3, 55, 56). In this
structure, N peptides form a central trimeric coiled coil (N
trimer), creating grooves into which C peptides bind. This
structure, in conjunction with the dominant-negative inhibitory
properties of exogenous N and C peptides, suggests a mecha-
nism for Env-mediated entry (10, 22, 58–60).
During entry, gp41 forms an extended prehairpin interme-
diate that leaves the exposed N-trimer region vulnerable to
inhibition for several minutes (18, 35). This intermediate ulti-
mately collapses as the C-peptide regions bind to the N-trimer
grooves to form a trimer of hairpins (six-helix bundle), juxta-
posing viral and cellular membranes and inducing fusion. En-
fuvirtide (Fuzeon), the only clinically approved HIV fusion
inhibitor, is a C peptide that binds to part of the N-trimer
groove and prevents six-helix bundle formation in a dominant-
negative manner (61). Enfuvirtide is active in patients with
multidrug resistance to other classes of inhibitors and is a
life-prolonging option for these patients (30, 31). However,
enfuvirtide use is restricted to salvage therapy due to several
limitations, including (i) high dosing requirements (90 mg,
twice-daily injections), (ii) high cost (!$30,000/year/patient in
the United States), and (iii) the rapid emergence of resistant
strains (21, 47).
A deep hydrophobic pocket at the base of the N-trimer
groove is an especially attractive inhibitory target because of its
high degree of conservation (3, 12, 48), poor tolerance to
substitution (4, 34), and critical role in membrane fusion (2).
Indeed, this region is conserved at both the amino acid level
(for gp41 function in membrane fusion) and the nucleotide
level (for the structured RNA region of the Rev-responsive
element). Enfuvirtide binds to the N-trimer groove just N
terminal to the pocket and is significantly more susceptible to
resistance mutations than 2nd-generation C-peptide inhibitors,
such as T-1249, that also bind to the pocket (8, 13, 29, 44, 46,
47, 58).
Peptide design, molecular modeling, and small-molecule
screening have produced a diverse set of compounds that in-
teract with the gp41 pocket and inhibit HIV-1 entry with mod-
est potency, but often with significant cytotoxicity (7, 14, 15, 17,
23, 24, 26, 34, 51, 54). The first direct evidence that pocket-
specific binders are sufficient to inhibit HIV entry came with
the discovery of protease-resistant D-peptides identified using
mirror-image phage display (12). In this technique, a phage
library is screened against a mirror-image version of the target
protein (synthesized using D-amino acids) (50). By symmetry,
mirror images (D-peptides) of the discovered sequences will
bind to the natural L-peptide target. As the mirror images of
naturally occurring L-peptides, D-peptides cannot be digested
by natural proteases. Protease resistance provides D-peptides
theoretical treatment advantages of extended survival in the
body and possible oral bioavailability (41, 42, 49).
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These 1st-generation D-peptide entry inhibitors possess po-
tency against a laboratory-adapted isolate (HXB2) at low to
mid-!M concentrations (12). We previously reported an affin-
ity-matured 2nd-generation D-peptide called PIE7, pocket-spe-
cific inhibitor of entry 7 (57). A trimeric version of PIE7 is the
first high-affinity pocket-specific HIV-1 inhibitor and has po-
tency against X4-tropic (HXB2) and R5-tropic (BaL) strains at
sub-nM concentrations. However, significant further optimiza-
tion is required to create a robust clinical candidate for two
reasons. First, this D-peptide is much less potent (requiring
high nM concentrations) against JRFL, a primary R5-tropic
strain. Therefore, improved PIE potency is necessary to com-
bat diverse primary strains. Second, by improving the affinity of
our inhibitors for the pocket target, we hope to provide a
reserve of binding energy that will delay the emergence of drug
resistance, as described below.
We and others have reported a potency plateau for some
gp41-based fusion inhibitors that is likely imposed by the tran-
sient exposure of the prehairpin intermediate (9, 27, 53, 57).
For very high-affinity inhibitors, association kinetics (rather
than affinity) limits potency so that two inhibitors with signif-
icantly different affinities for the prehairpin intermediate can
have similar antiviral potencies. We proposed that overengi-
neering our D-peptides with substantial affinity beyond this
potency plateau would provide a reserve of binding energy that
would combat affinity-disrupting resistance mutations (57).
Such a resistance capacitor should also prevent the stepwise
accumulation of subtle resistance mutations in Env by elimi-
nating the selective advantage that such mutants would other-
wise confer.
Here, we report on the design and characterization of a
3rd-generation pocket-specific D-peptide, PIE12-trimer, with
"100,000-fold improved target binding compared to that of
the best previous D-peptide, significantly broadened inhibitory
potency, and an enhanced resistance capacitor that provides a
strong barrier to viral resistance. We achieved this increased
potency via structure-guided phage display and crosslinker op-
timization. PIE12-trimer has a dramatically improved resis-
tance profile compared to the profiles of earlier D-peptides, as
well as those of enfuvirtide and T-1249. These results validate
the resistance capacitor hypothesis and establish PIE12-trimer
as a leading anti-HIV therapeutic candidate.
MATERIALS AND METHODS
Peptide synthesis. All peptides were synthesized as described previously (57).
All dimers and trimers except PIE12-trimer were made essentially as described
using bis-dPEG5 NHS ester (where PEG is polyethylene glycol and NHS is
N-hydroxysuccinimide; catalog no. 10224; Quanta BioDesign); PIE12-trimer was
synthesized using the following higher-yield protocol. PIE12-GK (2 mM) was
reacted with bis-dPEG5 NHS ester crosslinker (1 M stock in dimethylacetamide)
at a 1:20 (peptide/PEG) molar ratio in 100 mM HEPES (pH 7.8 to 8) for 90 s at
room temperature (RT). The reaction was stopped by addition of acetic acid to
5% and 3 M guanidine HCl (GuHCl) and purified by reverse-phase high-pres-
sure liquid chromatography (RP-HPLC; C18 column; Vydac). This product ("3
to 5 mM) was reacted at a 2:1 molar excess with PIE12-GKK in dimethylacet-
amide buffered by triethylamine (pH 7.5) for 75 min and purified by RP-HPLC
(C18 column; Vydac).
Phage display vector design. Use of a commercially available phage library
cloning system (NEB) allowed us to relocate cloning sites away from the flanking
regions (38). We redesigned the regions immediately outside the flanking resi-
dues in our cloning vector in order to structurally isolate them and minimize any
bias caused by flanking sequence randomization. Our library peptides are dis-
played as fusions to the phage p3 protein, which contains an N-terminal leader
sequence that is cleaved by Escherichia coli secretion signal peptidases. In the
original vector, the N-terminal flanking residues of the library peptides are
immediately adjacent to the secretion signal. Due to proximity to the secretion
signal cleavage site, it is likely that randomization of these residues would
differentially affect library-p3 protein secretion and peptide presentation on the
phage surface. This bias would confound the selection of N-terminal flanking
sequences solely on the basis of their affinity for the N trimer. To avoid this bias,
we introduced a five-amino-acid spacer to structurally isolate the cleavage site
from the randomized N-terminal flanking residues. We choose the N-terminal
residues (KIEEG) from maltose binding protein (MBP) as the spacer sequence,
since MBP is very efficiently cleaved during secretion from E. coli.
We have observed that mutations in the C-terminal sequence that links the
peptide to the phage p3 protein can also create undesirable selection bias (pre-
sumably by allowing the C terminus of the D-peptides to form a continuous helix
with the N terminus of p3, thus enhancing peptide presentation to the target)
(57). Therefore, a flexible GGGS spacer was inserted after the C-terminal flank-
ing residues to structurally isolate them from the N terminus of p3.
To validate this new phage display vector, we used it to clone an earlier PIE
(PIE2) along with a mutant (PIE2-AAA) which had previously been observed to
enhance phage affinity for the pocket target via mutation of the linker between
the library peptide and p3, although this mutation did not enhance inhibitor
potency when incorporated into a D-peptide (57). We assayed the target binding
affinity of the resultant phage (#) and compared it to that of phage produced
with the previous phage vector. In the previous phage vector, PIE2-AAA-#
“cheated” in order to bind to the target with an "70-fold more affinity than
PIE2-#, but this difference was abolished in the modified vector (data not
shown). Furthermore, sequencing revealed that N-terminal flanking residues
from the amplified phage library prior to selection were random, indicating a lack
of bias due to signal peptidase cleavage efficiency.
Phage display. An 8-mer flanking library phage display was performed essen-
tially as described previously (57). Four rounds of mirror-image solution-phase
phage display were performed by incubating (for 2 h at RT) 1010 phage (ampli-
fied from the previous round) with 10 nM biotinylated D-IZN17 (a mimic of the
D-peptide gp41 pocket target) in the presence of escalating soluble competitor
(L-2K-PIE2) (10, 30, 90, and 360 !M for rounds 1 to 4, respectively) (57).
Phage-bound D-IZN17 was rapidly captured from solution using Dynal T1
streptavidin-coated magnetic beads (Invitrogen) and briefly washed 3 times with
500 !l of 0.1% Tween 20 in Tris-buffered saline (wash buffer contained 100 !M
D-biotin for the 1st wash). Phage was eluted in 50 !l of glycine (pH 2.2) elution
buffer (10 min at RT) and neutralized with 7.5 !l of 1 M Tris, pH 9.1. The
amplified phage library was sequenced prior to the first round of selection to
confirm randomization, and preamplified eluted phage was sequenced following
each round. All phage binding experiments were performed using the same
protocol described above using 270 !M L-PIE2 soluble competitor. A 7-mer
phage display was performed using a similar protocol.
Crystal growth and data collection. The original form of PIE12 (see Table 1)
contains a C-terminal GK extension and did not yield highly diffracting crystals
in complex with IQN17, a gp41 pocket mimic. Variants of PIE12 instead con-
taining an N-terminal K or KG extension (K-PIE12, KHPCDYPEWQWLCEL;
KG-PIE12, KGHPCDYPEWQWLCEL) crystallized in complex with IQN17
under a variety of conditions. In each case, the reservoir (850 !l) comprised a
solution from a commercially available crystallization screen, and the crystalli-
zation drop was prepared by mixing 0.3 or 0.5 !l of the IQN17-PIE12 or
IQN17-PIE71 protein solution (1:1.1 molar ratio, 10 mg/ml total in water) with
0.3 !l of the reservoir solution. Crystals typically grew in 1 to 10 days. All crystals
were grown by sitting-drop vapor diffusion. IQN17-PIE12 form I crystals (KG-
PIE12) were grown at 21°C in Hampton Scientific condition Screen II 48 (10%
PEG 20,000, 0.1 M bicine, pH 9.0, 2% dioxane). IQN17-PIE12 form II crystals
(KG-PIE12) were grown at 21°C in Emerald Biosystems condition Cryo-II 37
(50% ethylene glycol, 0.1 M imidazole, pH 8.0). IQN17-PIE12 form III crystals
(K-PIE12) were grown at 4°C in Emerald Biosystems condition Cryo-II 25 (40%
2-methyl-2,4-pentanediol (MPD), 0.1 M N-cyclohexyl-3-aminopropanesulfonic
acid (CAPS) [pH 10.5]). IQN17-PIE71 crystals were grown at 21°C in Qiagen
PACT crystallization condition G4 (20% PEG 3350, 0.2 M potassium thiocya-
nate, 0.1 M bis-Tris propane, pH 7.5).
Crystals were mounted in a nylon loop and either directly cryocooled by
plunging them into liquid nitrogen or cryocooled following brief (20 s) immer-
sion in 20 !l crystallization buffer with 30% (IQN17-PIE12) or 15% (IQN17-
PIE71) added glycerol. Crystals were maintained at 100 K during data collection.
Data were collected either in the laboratory using a rotating copper anode X-ray
generator or at a synchrotron beam line. Data were processed using the DENZO
and SCALEPACK programs (40). All structures were determined by molecular
replacement using the PHASER program (33) with IQN17-PIE7 as the search
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model. The models were rebuilt using the O program (25) and refined against a
maximum-likelihood target function using the REFMAC program (36). Struc-
tures were checked using the MolProbity program (6) (see Table 2 for data and
refinement statistics).
Explanation of Lys placement. We were concerned that direct C-terminal
addition of Lys would not be well tolerated because the D-peptide C-terminal
region forms an ! helix critically involved in the pocket-binding interface, with
the C terminus itself being amidated for helix stability. Therefore, we inserted a
Gly between the original C terminus of PIE7 and the C-terminal Lys, both to cap
the helix and to separate the Lys from the binding interface. Unexpectedly,
PIE7-GK-monomer is slightly more potent than PIE7 (see Table 1). A version of
PIE7 containing an N- and C-terminal Lys (K-PIE7-GK) has the same potency
as PIE7-GK (data not shown), indicating a beneficial effect imposed by the
C-terminal Gly-Lys, as opposed to a deleterious effect created by a single Lys at
the N terminus. This benefit is likely the reason that the linkage consisting of an
"22-Å cross-linker at the C terminus whose spacer arm consists of 5 PEGs (C5C)
results in a potency slightly superior to that of the N5C linkage (see Table 1).
Viral infectivity assays. Pseudovirion infectivity assays were performed as
described previously (57). Purified lyophilized inhibitors were dissolved in water
(monomers) or 50 mM HEPES, pH 7.5 (dimers and trimers), to make high-
concentration stocks. For HEPES-containing samples, all media were adjusted
so that the HEPES content matched that in the sample with the highest HEPES
concentration (typically, "1 mM). HEPES at higher concentrations (e.g., 3 mM)
enhanced infectivity up to "15% but had minimal effect at !0.5 mM. The
Monogram Biosciences PhenoSense Entry and peripheral blood mononuclear
cell (PBMC) assays were performed as described previously (43, 52).
CD studies. Samples were prepared with 2 #M IZN17, a 1.1$ molar ratio of
inhibitor to target binding sites, phosphate-buffered saline (PBS; 50 mM sodium
phosphate, 150 mM NaCl, pH 7.4), and 2 M GuHCl in a total volume of 2.5 ml.
Thermal melts were performed by melting the sample in a square 1-cm cuvette
from 25°C to 90°C (or 93°C for PIE12-trimer) in 2°C increments with 2 min of
equilibration. To show reversibility, reverse melts were performed on each sam-
ple from 90°C to 30°C in 10°C increments with 5 min of equilibration. Data were
averaged from a 30-s collection on an Aviv model 410 circular dichroism (CD)
spectrapolarimeter.
For each sample, the CD data followed a smooth sigmoid transition as the
sample was heated or cooled. The data were smoothed in the Kaleidagraph
program (Synergy Software) using 2 points from both sides. The derivative value
of the smoothed data was used to determine the point with the steepest rate of
change on the melt curve, which is the melting temperature (Tm).
Passaging studies. Laboratory-adapted HIV-1 strain NL4-3 was generated by
transient transfection of proviral DNA (pNL4-3) into 293T cells using Lipo-
fectamine (Invitrogen). Cell-free supernatants containing virus were collected
48 h posttransfection and used to infect 5 $ 105 CEM-1 cells in RPMI 1640
medium (0.5 ml). Virus was serially propagated once a week by 1:5 dilution of
cell-free viral supernatants into fresh CEM-1 cells (5 $ 105 cells, 0.5 ml) in the
absence or presence of inhibitor (PIE7-dimer, PIE12-dimer, or PIE12-trimer).
Viral titers were monitored biweekly by p24 antigen enzyme-linked immunosor-
bent assay (PerkinElmer). The inhibitor concentration started at approximately
the 50% inhibitory concentrations (IC50s; 20 nM for PIE7-dimer; 1 nM for
PIE12-dimer, and PIE12-trimer) and was raised 1.5- to 2-fold when p24 antigen
levels in inhibitor-containing cultures approached that in inhibitor-free cultures
(usually 2 to 3 weeks for PIE7-dimer). PIE12-dimer and PIE12-trimer required
a slower escalation strategy with prolonged incubation at a fixed inhibitor con-
centration for 5 to 15 weeks before escalation.
To identify PIE7-dimer escape mutations, viral RNA was isolated from cell-
free supernatants of at least two cultures independently propagated in either the
presence (resistant virus) or absence (control virus) of inhibitor (Qiagen RNA
purification kit). Env cDNA was generated by reverse transcription (Eppendorf
cMaster RTplus system and cMaster reverse transcription kit), amplified by
PCR, and sequenced in five stretches (Thomas Jefferson University Nucleic Acid
Facility). To confirm selected mutations in the gp41 N-peptide region, the cDNA
segment encoding the gp41 ectodomain was reamplified by PCR and subcloned
into the pAED4 vector, and the plasmid DNA from three or more individual
clones was sequenced. The substitutions E560K and V570I were observed in all
sequences from PIE7-dimer-resistant virus but were not observed in any se-
quence from control virus. An expression plasmid for HXB2 Env (pEBB_HXB2
Env) incorporating these substitutions was generated using site-directed muta-
genesis (QuikChange; Stratagene) and was utilized in the pseudoviral infectivity
assay described above.
Protein Data Bank accession numbers. The Protein Data Bank (PDB) acces-
sion numbers for the PIE12-IQN17 complex are 3L35, 3L36, and 3L37 for crystal
forms I, II, and III, respectively, and 3MGN for the PIE71-IQN17 complex.
RESULTS
Structure-guided phage display to optimize flanking resi-
dues. PIE inhibitors consist of a short core sequence sur-
rounded by a disulfide bond that imparts structural rigidity
required for binding (Table 1) (12). The large jump in affinity
between our 1st-generation (12) and 2nd-generation (57) in-
hibitors was accomplished by optimizing this core sequence.
There were also four fixed flanking residues outside the disul-
fide that arose from phage library cloning restrictions, Gly-Ala
on the N terminus and Ala-Ala on the C terminus. Interest-
ingly, our cocrystal structures of D-peptides in complex with a
mimic of its gp41 pocket target (IQN17) reveal significant
contacts between these presumed inert flanking residues and
the pocket (12, 57). Thus, we reasoned that their optimization
would likely lead to improved D-peptide affinity for the pocket.
To optimize these flanking residues, we used a commercially
available phage library cloning system (NEB) that allowed us
to relocate cloning sites away from the flanking regions (38).
We redesigned the regions immediately outside the flanking
residues in our cloning vector in order to structurally isolate
them and minimize any bias caused by flanking sequence ran-
domization. Using this vector, we constructed a phage library
that varied only these four residues in the context of our
previously optimized PIE7 core sequence (XXCDYPEWQW
LCXX). After four rounds of panning, our phage library
showed "100-fold improved binding to a gp41 pocket mimic
(D-IZN17) compared to that of clonal PIE7 phage with the
original GA/AA flanking sequence. We extensively sequenced
this phage pool to identify a consensus sequence, H(A/P)-
[PIE7 core]-(R/K/E)L, as well as five dominant individual se-
quences. Using a phage clone binding assay, we found that
these sequences bound the gp41 pocket 70- to 900-fold more
tightly than PIE7, with PIE12 (HP-[PIE7 core]-EL) having the
highest affinity (data not shown).
TABLE 1. D-peptide inhibition datae
Sample Sequence
IC50 (nM)a
HXB2 JRFL
PIE7 KGA%PIE7&AA 620b 24,000b
PIE7-GK GA%PIE7&AAGK 390 16,000
PIE7-GKK GA%PIE7&AAGKK 380 19,000
PIE12 HP%PIE7&ELGK 37 580
PIE13c HP%PIE7&KL 41 1,500
PIE14 HP%PIE7&RLGK 33 1,100
PIE15 HA%PIE7&ELGK 67 1,400
N9N(PIE7)2 (KGA%PIE7&AA)2 1.9b 2,300b
N5C(PIE7)2 GA%PIE7&AAGKKGA%PIE7&AA 0.6 300
C5C(PIE7)2 (GA%PIE7&AAGK)2 0.5 200
C5C(PIE12)2 (HP%PIE7&ELGK)2 0.4 14
N9N(PIE7)3 (KGA%PIE7&AA)3d 0.3b 220b
C5C(PIE7)3 (GA%PIE7&AAGK)3d 0.1 6.7
C5C(PIE12)3 (HP%PIE7&ELGK)3d 0.5 2.8
C37 1.4b 13b
Enfuvirtide 3.7b 5.0b
a The IC50 standard error of the mean is '25% for duplicate assays for all
values.
b Values are from reference 57.
c PIE13 does not include a C-terminal GK extension because its C-terminal
flanking sequence contains a Lys residue.
d The central peptide of each trimer has two tandem Lys residues (not shown).
e PIE7, CDYPEWQWLC, or PIE7 core motif.
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Enhanced potency of 3rd-generation D-peptides. We synthe-
sized D-peptides corresponding to the top three phage se-
quences in the binding assay (PIE12, PIE13, and PIE14) and
tested their antiviral potencies in a pseudovirion entry assay
(Table 1 and Fig. 1). Pairwise comparisons of both phage
binding and inhibitor potency indicate that Pro is preferred
over Ala at position 2 and Glu is preferred over Arg or Lys at
position 13. As predicted from the phage binding assay, PIE12
has the best potency and is !40-fold more potent than PIE7
(our best previously reported monomer) against strain JRFL.
Crystal structure of PIE12. To better understand the
sources of PIE12’s improved binding and potency, we crystal-
lized PIE12 in complex with the N-trimer pocket mimic
IQN17. Data were collected from three crystal forms (Table 2)
at between 1.45- and 1.55-Å resolution. Each IQN17 trimer
from the three crystal forms reported here and from the PIE7
structure (PDB accession number 2R5D) agreed well with one
another (root mean square deviation [RMSD], 0.6 to 1.2 Å) on
the basis of the least-squares overlap on all C" atoms (residues
1 to 45 of all three chains). The structures suggest two sources
of the improved affinity of PIE12 for IQN17 compared to that
of PIE7. First, the new N-terminal flank residues (His1 and
Pro2) form favorable ring stacking interactions with the pocket
(IQN17-Trp571) (Fig. 2). Second, the substitution of Leu for
Ala in the C-terminal flank sequence buries an additional
!50-Å2 hydrophobic surface area in the pocket. Neither of
these new interactions with the flanking sequence perturbs the
original pocket-binding structure of the core PIE7 residues.
Importantly, the structures reveal that PIE12’s improved affin-
ity does not result from new interactions with less conserved
FIG. 1. Optimization of flanking residues enhances PIE potency.
Each point represents the average of quadruplicate measurements from a
representative pseudovirion entry inhibition assay (JRFL strain) normal-
ized to the measurement for an uninhibited control. Error bars represent
the standard errors of the means. PIE12 is !2-fold more potent than
PIE13 or PIE14 and is !25-fold more potent than PIE7-GK.
TABLE 2. PIE12 and PIE71 crystallographic data and refinement statistics
Data
Result for PIE12 crystal:
Result for PIE71 crystal
Form I Form II Form III
Space group P21 R3 P321 P21
Resolution (Å) 30.0–1.55 (1.61–1.55)a 30.0–1.45 (1.50–1.45) 30.0–1.45 (1.50–1.45) 30.0–1.40 (1.45–1.40)
No. of reflections measured 113,335 98,687 186,351 468,599
No. of unique reflections 25,088 10,475 14,802 82,774
Redundancy 4.5 9.4 12.6 5.7
Completeness (%) 86.5 (66.8) 97.1 (80.1) 99.7 (96.6) 98.2 (97.6)
#I/$I%b 18 (2.4) 19 (3.1) 17 (2.7) 15 (2.0)
Mosaicity (degree) 0.44 0.37 0.45 0.29
Rsymc 0.051 (0.250) 0.058 (0.102) 0.107 (0.235) 0.052 (0.316)
Refinement
Resolution (Å) 30.0–1.55 (1.59–1.55) 30.0–1.45 (1.49–1.45) 30.0–1.45 (1.49–1.45) 30.0–1.40 (1.44–1.40)
No. of reflections used for refinement 23,765 9,448 13,629 80,532
No. of reflections in Rfreed set 1,273 1,026 1,136 1,654
Rcryste 0.232 (0.465) 0.234 (0.301) 0.243 (0.299) 0.261 (0.306)
Rfree 0.288 (0.624) 0.264 (0.392) 0.278 (0.350) 0.288 (0.335)
RMSD bonds (Å)/angles (degrees) 0.012/1.440 0.013/1.693 0.010/1.530 0.009/1.094
#B%g
All atoms (Å2)/no. of atoms 23.7/1,172 31.9/384 29.2/384 Molf 1, 24.3/1,555; mol 2,
36.0/1,491
PIE12 molecules only (Å2)/no. of atoms 21.3/420 30.8/144 25.9/144 Mol 1, 18.3/368; mol 2,
39.9/322
Water molecules (Å2)/no. of water atoms 32.0/197 38.0/36 40.6/49 39.9/389
&/'h most favored (%) 100 98.1 100 99.0
a Values in parentheses refer to data in the high-resolution shell.
b #I/$I%, average intensity of a group of reflections divided by the average standard deviation (sigma) of the same group of reflections.
c Rsym ( )!I * #I%!/)I, where I is the intensity of an individual measurement and #I% is the corresponding mean value.
d Rfree is the same as Rcryst calculated with a randomly selected test set of reflections that were never used in refinement calculations.
e Rcryst ( )!!Fo! * !Fc!!/)!Fo!, where !Fo! is the observed and !Fc! is the calculated structure factor amplitude.
f Mol, molecule.
g #B%, temperature factor.
h &/+, dihedral angles.
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regions outside the pocket that might render PIE12 more vul-
nerable to resistance mutations.
Discovery and structure of a 7-mer D-peptide. The core
sequence of PIE7 and PIE12 comprises 8 residues flanked by
cysteines (8-mer). Modeling based on our 8-mer D-peptide/
IQN17 crystal structures suggests that a 7-mer core is compat-
ible with pocket binding of the WXWL consensus and forma-
tion of a disulfide bond (57). Previously, we saw that decreasing
the size of the PIE core (from 10 to 8 residues) led to dramat-
ically increased pocket binding (57), so we reasoned that fur-
ther decreasing the size of the core might lead to additional
potency gains. To explore this alternative geometry, we used a
mirror-image discovery process similar to that employed with
8-mers to identify a 7-mer, PIE71 (FVCPPEWRWLCDL).
PIE71 contains the same WXWL motif found in 8-mer and
10-mer pocket binders and inhibits strain HXB2 entry with an
IC50 of 410 nM (data not shown), which is !1.5 fold better
than that of PIE7 but an order of magnitude worse than that of
PIE12.
To gain a better understanding of the 7-mer binding solu-
tion, we determined a cocrystal structure of PIE71 in complex
with IQN17 (Table 2). The key residues involved in the binding
interface (WXWL) adopt nearly superposable conformations
to those observed in PIE7 and PIE12, as do the C-terminal
flank residues. However, the two structures deviate signifi-
cantly at the N terminus (Fig. 2 and 3). Specifically, the 7-mer’s
disulfide bond is shifted much closer to the pocket, which
directs the N-terminal flank residues away from the pocket
region. As a result, the N-terminal flanking residues (Phe-Val)
only graze the pocket, whereas PIE12’s N-terminal flanking
residues have an intimate interaction. So although the 7-mer is
compatible with pocket binding, the smaller core is too con-
strained to allow optimal binding of the flank residues to the
pocket. Due to this decreased binding interface and therefore
decreased potency, we decided not to pursue the 7-mer geom-
etry further.
Optimization of crosslinker length and geometry. We pre-
viously took advantage of the trimeric nature of the gp41
pocket target to geometrically increase the PIE7 binding affin-
ity by cross-linking it into dimers and trimers (57). PIE7 has an
N-terminal lysine, which furnishes a unique primary amino
group (the N terminus is acetylated) and which was added for
solubility. This lysine was used to produce dimers via reaction
with a bis-PEG NHS ester crosslinker (NHS esters selectively
react with primary amino groups). Trimers were produced by
cross-linking two PIE7s to a central peptide with two lysines at
the N terminus (2K-PIE7).
We hypothesized that the strength of the avidity effect is
related to the length of the crosslinker and that shorter
crosslinkers that still allow simultaneous binding to multiple
pockets could strengthen potency. For the original N- to N-
terminal linkage, we used a crosslinker with an !35-Å spacer
arm consisting of 9 PEG units (N9N linkage). However, our
crystal structures of D-peptides in complex with IQN17 reveal
that C- to C-terminal or N- to C-terminal linkages could be
significantly shorter and could be spanned by an !22-Å
crosslinker whose spacer arm consists of 5 PEGs (C5C and
N5C linkages). Therefore, we relocated Lys to the C terminus
of PIE7 (PIE7-GK) in order to make the N5C heterodimers
and C5C homodimers (see Materials and Methods for addi-
tional details).
The resulting N5C- and C5C-PIE7-dimers have similar po-
tencies that are significantly enhanced compared to the po-
tency of our previous N9N-PIE7-dimer (Table 1 and Fig. 4A).
On the basis of these data, we chose C5C connections as our
standard linker, since they are simpler to produce than the
hetero-N5C linkage. Here, all dimers and trimers use the C5C
linkage unless otherwise specified. Combining our new opti-
mized flanking residues and linkages, we produced PIE12-
dimer and PIE12-trimer. Both are extremely potent against the
difficult-to-inhibit primary strain JRFL (low-nanomolar IC50s;
Fig. 4B; Table 1), being up to 2 orders of magnitude more
potent than our best previously described D-peptide (N9N
PIE7-trimer) (57).
Breadth against a diverse multiclade panel. HIV-1 has
jumped from chimpanzees to humans at least three separate
times, giving rise to groups M, N, and O (19). The main group
(group M) accounts for "99% of all HIV-1 infections world-
FIG. 2. Crystal structure of PIE12 binding to IQN17. Trp571 of the
gp41 pocket (gray) and the N-terminal flank residues (dH1 and dP2) of
PIE12 (green) appear to stabilize binding via ring-stacking interac-
tions. The disulfide bond (yellow) is shown in the background.
FIG. 3. Crystal structure of PIE71 binding to IQN17. The N-ter-
minal flank residues (dF1 and dV2) of PIE71 (orange) are directed
away from the pocket compared to the structure in PIE12 (Fig. 2). The
disulfide bond (yellow) is shown in the background.
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wide (32). HIV’s high mutation rate has led to the emergence
of diverse subtypes within group M that are categorized as
clades A to D, F to H, J, and K and various circulating recom-
binant forms (CRFs; e.g., AE and BF). In 2000, clades A to D
were estimated to represent !90% of HIV infections (39);
however, in recent years CRFs have become more prevalent
(1). Different subtypes contain up to 35% sequence diversity in
Env, often causing antibodies raised against a particular strain
to be ineffective against others (20).
To ensure that our pocket-specific D-peptides are potent and
broadly neutralizing against the most common subtypes of
HIV, we measured the potency of PIE7-trimer, PIE12-trimer,
and PIE12 (with enfuvirtide as a control inhibitor) using the
PhenoSense Entry pseudovirion assay (Monogram Bio-
sciences) (Table 3) (43). The inhibitors were tested against a
panel of 23 viruses pseudotyped with clonal and polyclonal
envelopes representing clades A to D, several CRFs, and en-
fuvirtide-resistant strains. Both PIE7 and PIE12-trimers po-
tently inhibited all strains tested, though PIE12-trimer was
generally a superior inhibitor (and in all cases more potent
than enfuvirtide). While PIE12-monomer is much less potent
than PIE12-trimer, it is also broadly active. Interestingly,
PIE12-trimer is "10-fold more potent than PIE7-trimer
against polyclonal virus from clades B and C (samples ampli-
fied from patient plasma), which is consistent with a resistance
capacitor mechanism for maintaining potency in the presence
of various Env sequences. All of the D-peptide inhibitors are
unaffected by enfuvirtide resistance mutations. Additionally,
lack of inhibition against a murine leukemia virus (MLV) con-
trol indicates that these inhibitors are specific and nontoxic in
this assay.
Breadth against replication-competent primary viral iso-
lates on PBMCs. To more closely mimic in vivo infection and
further establish inhibitory breadth, we also tested the ability
of PIE7-trimer, PIE12-trimer, and PIE12 to inhibit PBMC
infection by replicating primary strains, again with enfuvirtide
as a control (Table 4). These data confirm the potent and
broad inhibitory activities of PIE7 and PIE12-trimer against all
group M strains tested, including several CRFs. Toxicity was
not observed on these cells at inhibitor concentrations up to 1
#M (the highest concentration tested), demonstrating a high
therapeutic index for the trimers. Interestingly, the inhibitors
are more potent in this assay than in the PhenoSense Entry
assay, which may be due to differential receptor expression
levels between the two cell types (45).
Notably, two group O strains were also tested in this assay
and are much less sensitive to inhibition than group M strains.
Group O contains several mutations (compared to the se-
quence of group M) in the pocket, including Q567R, T569S,
K574R, Q577R, and V580L. The crystal structures of PIE7 and
FIG. 4. Optimization of linkage geometry. Each point represents the average of quadruplicate measurements from a representative
pseudovirion entry inhibition assay (JRFL strain) normalized to the measurement for the uninhibited control. Error bars represent the standard
errors of the means. (A) Comparison of N9N to C5C linkages; (B) PIE7 versus PIE12-dimers and trimers (all C5C linkages).
TABLE 3. PhenoSense Entry assay data
HIV-1
isolate Subtype
IC50 (nM)
PIE7-trimer PIE12-trimer PIE12-monomer Enfuvirtide
Aa A 5.5 4.1 2,300 18
92RW008 A 2.0 1.0 1,400 7.2
92UG031 A 18 4.2 2,600 20
94KE105 AC 16 0.7 1,900 13
CMU02 AE 32 12 1,500 16
Ba B 140 13 3,300 30
1168 B 54 31 4,700 140.0
BaL B 2.0 2.5 1,700 10
ENFr1a B 2.0 0.8 790 760
ENFr2a B 0.7 1.0 300 5,400
HXB2 B 0.1 0.3 50 2.6
JRCSF B 13 3.4 1,100 14
JRFL B 21 5.7 1,900 7.9
NL4.3 B 0.3 0.4 150 62
SF162 B 3.4 4.5 940 34
98CN009 BC 0.4 0.4 320 7.9
93BR029 BF 1.5 0.9 750 12
Ca C 220.0 26 5,100 71
97ZA012 C 2.0 0.7 1,500 10
98IN022 C 1.1 1.1 820 6.9
21068 C 6.6 5.0 1,800 47
Da D 3.1 3.2 820 17
92UG005 D 3.9 2.5 2,000 10
aMLV !10,000 !10,000 !500,000 !15,000
a Polyclonal viral envelopes amplified from patient plasma.
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PIE12 in complex with IQN17 reveal that, of these residues,
the D-peptide directly interacts only with K574 (via a hydro-
phobic interaction) and Q577 (via hydrogen bonds). Group O
gp41 has several other mutations in the groove just outside the
pocket (i.e., H564E) that could also affect PIE potency (e.g., by
slowing the association rate). It will be interesting to analyze
the effects of these mutations in a group M (e.g., strain HXB2
or JRFL) background to see if they are responsible for the loss
of potency.
Evidence for a charged resistance capacitor.With the design
of PIE12-trimer, we now observe strong evidence for a highly
charged resistance capacitor in which the PIE12-trimer pocket-
binding affinity vastly exceeds the inhibitory potency. Compar-
ing PIE7 and PIE12-trimers, we observe similar potencies
against pseudovirion entry (Fig. 4B; Table 1), although we
expect their target affinities to be extremely different.
Due to extraordinarily slow off rates, direct measurements of
the pocket affinities for PIE7 and PIE12-trimers via surface
plasmon resonance, used for earlier D-peptides (57), were not
possible. Since the binding affinity of inhibitors correlates with
the stability of inhibitor-target complexes, we used thermal
denaturation monitored by CD to measure the relative stabil-
ities of each IZN17-inhibitor complex and infer the relative
affinities of our ultra-high-affinity binders. The melts were per-
formed in 2 M GuHCl to destabilize the complexes and shift
their melting points into an observable range (below 100°C).
The normalized thermal melts for each IZN17-inhibitor
complex are plotted in Fig. 5, with Tm values being shown in
the key. As expected, PIE12-trimer forms the most stable com-
plex and has a Tm 8°C higher than that of the next most stable
inhibitor complex (PIE7-trimer). PIE12 also forms a more
stable complex than PIE7, as expected. Our previous experi-
ence showed that improvements in monomer affinity translated
to approximately squared and cubed improvements in the cor-
responding dimers and trimers (57). On the basis of PIE12-
trimer’s optimized C5C linkage (35-fold improved antiviral po-
tency over that of the trimer with an N9N linkage; strain JRFL
data) and the !25-fold difference in monomer potency be-
tween PIE7 and PIE12 (JRFL data), we estimate that PIE12-
trimer binds to gp41 "105-fold (35 # 253) more tightly than
N9N PIE7-trimer. This predicted binding at subfemtomolar
concentrations translates to a resistance capacitor charged to
!6 kcal/mol against strain JRFL. Interestingly, the potency
plateau lies at a slightly better potency for trimers than for
dimers, likely due to their faster association rates (i.e., three
versus two opportunities for initial collision with the target).
Selection of resistant strains. To measure the resistance
profile of our D-peptide inhibitors and test our resistance
capacitor hypothesis, we conducted viral passaging studies
with escalating inhibitor concentrations to select for resis-
tant strains. These studies initially used PIE7-dimer, which
was available from our previous study (57) and inhibits the
parental strain, NL4-3, with an IC50 of !20 nM. By doubling
the PIE7-dimer concentration every 2 to 3 weeks, we ob-
tained stable viral cultures in 2,000 nM inhibitor within 20
weeks of propagation. In comparison, we were able to ob-
tain high-level enfuvirtide resistance ("1,000-fold) in only
!3 weeks using a similar protocol (H. K. Steger et al.,
submitted for publication).
Sequencing the N-peptide region of PIE7-dimer-resistant
viruses revealed two selected mutations: E560K and V570I.
These substitutions in the context of HXB2 pseudovirions con-
ferred !400-fold resistance to PIE7-dimer. These mutations
also dramatically weaken the binding of D-peptides to the gp41
pocket but not the C-peptide inhibitor C37 (M. J. Root et al.,
unpublished data). It is not obvious from the PIE7 structure
how these mutations weaken PIE7 binding. Despite this loss of
affinity, the escape mutations had a minimal effect on the
FIG. 5. Stability of D-peptide complexes. Normalized melting
curves of IZN17 alone and with D-peptide inhibitors were monitored
by CD in PBS–2 M GuHCl. Tm values are indicated in the key.
TABLE 4. PBMC assay data
HIV-1
isolate Subtype
IC50 (nM)
PIE7-trimer PIE12-trimer PIE12-monomer Enfuvirtide
92UG029 A 1.6 0.7 290 190
92UG037 A 0.1 0.2 36 41
93TH073 AE 0.6 0.8 270 200
CMU02 AE 0.2 0.4 300 44
CMU06 AE 0.3 0.4 210 5.7
IIIB B 0.3 0.8 140 28
BaL B 0.2 0.3 72 20
JRCSF B 0.1 0.1 120 7.0
JRFL B 0.5 0.3 110 1.7
93BR019 BF 1.7 4.7 170 "1,000
92BR025 C 15 5.2 "1,000 310
93IN101 C 0.4 0.4 160 22
92UG001 D 0.8 4.5 230 180
92UG046 D 0.1 1.2 170 130
93BR020 F 0.2 0.4 190 59
93BR029 F 0.2 0.8 86 19
G3 G 0.3 1.2 310 23
RU570 G 0.3 0.4 480 37
BCF01 Group O "1,000 "1,000 "1,000 330
BCF02 Group O "1,000 440 "1,000 0.4
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potencies of PIE12-dimer and PIE12-trimer, as well as the C37
control inhibitor (Fig. 6). This result is predicted by the resis-
tance capacitor hypothesis: affinity-disrupting escape muta-
tions selected in the presence of weaker-binding inhibitors
should be less disruptive to the potencies of tighter-binding
inhibitors.
The rapid inhibitor escalation strategy utilized to generate
PIE7-dimer resistance was not effective in generating HIV-1
resistant to PIE12-dimer or PIE12-trimer. Rather, the HIV-1
titer fell precipitously when inhibitor concentrations exceeded
20 nM (5 to 20 times the IC50). Instead, we switched to a much
slower escalation strategy with prolonged periods at stable
inhibitor concentrations (5 to 15 weeks). Resistant virus
emerged after 40 weeks of propagation in PIE12-dimer and
after 65 weeks of propagation in PIE12-trimer. These obser-
vations suggest that a strong resistance capacitor profoundly
delays selection of resistance mutations for these optimized
fusion inhibitors.
Sequencing of the pocket region of PIE12-trimer-resistant
viruses reveals only one mutation, Q577R. Interestingly, this
substitution is present in nearly all group O isolates (including
BCF01 and BCF02; Table 4) but is rare among group M
isolates. Pseudovirions bearing Q577R confirm that this muta-
tion confers substantial resistance to PIE12-trimer (data not
shown). Examination of the PIE12 crystal structure shows that
Q577 makes hydrogen bonds with Glu7 and Trp10 in PIE12,
which may explain the disruptive effects of this mutation.
Q577R’s codon is predicted to disrupt the RRE stem-loop V
structure, since it base pairs with the invariant W571 codon
(Trp is encoded by only one codon).
DISCUSSION
PIE12-trimer is a D-peptide entry inhibitor with !80-fold
enhanced potency and an estimated "100,000-fold improved
binding affinity compared to those of the best previously re-
ported D-peptide. This dramatic improvement in affinity pro-
duces excellent breadth and a charged resistance capacitor to
combat the emergence of resistance mutations. Indeed, PIE12-
trimer was able to withstand the impact of resistance mutations
to earlier D-peptides and required a much longer selection (65
weeks) to generate resistant strains. Ongoing work is exploring
the mechanism of PIE7-dimer, PIE12-dimer, and PIE12-tri-
mer resistance and its relationship to group O’s insensitivity. A
key question is whether HIV can develop resistance to these
inhibitors independent of changes in affinity (e.g., kinetics) that
are capable of maintaining viral fitness.
Viral escape affects even the newest class of FDA-approved
HIV-1 drugs, integrase inhibitors. Resistance to raltegravir and
corresponding treatment failure were observed in a significant
subset of patients in both the phase II and III clinical studies
(5), and corresponding resistance mutations can be seen within
4 weeks when resistant virus is selected in viral passaging stud-
ies (28). Our studies indicate that PIE12-trimer is a promising
entry inhibitor that could overcome the limitations associated
with the two currently approved entry inhibitors, enfuvirtide
(high dosing, susceptibility to resistance) and maraviroc (Sel-
zentry; effective only against R5 viruses) and may also prove to
have a better resistance profile than even the newest class of
HIV-1 inhibitors.
In addition to being a possible therapeutic agent, PIE12-
trimer is an ideal candidate for a topical microbicide, as its
protease resistance would allow it to withstand the protease-
rich environment of the vaginal mucosa. In the absence of a
safe and effective HIV vaccine, a topical microbicide to pre-
vent the sexual transmission of HIV is an urgent unmet global
health need. The ultimate utility of PIE12-trimer as a micro-
bicide or therapeutic agent will be determined by advanced
preclinical and clinical studies, including characterization of
pharmacokinetics, in vivo toxicity, effectiveness in animal mod-
els of HIV infection (alone or in combination with other HIV
inhibitors), and optimization of formulations for microbicide
gels or vaginal rings.
More generally, the present work unequivocally shows that
D-peptide inhibitors can be designed with high potency and
specificity against natural L-protein targets. The D-peptide de-
sign methodology described here can be applied to diverse
biomedical applications, particularly for the many viruses that
share HIV’s hairpin-closing entry mechanism (e.g., influenza
virus, Ebola virus, respiratory syncytial virus, severe acute re-
spiratory syndrome coronavirus, Dengue virus, and West Nile
virus). Our resistance capacitor design strategy may also be
generally applicable for treating other rapidly evolving dis-
eases, especially when combined with recent advances in an-
ticipating likely structural sources of drug resistance (37). Fi-
nally, the development of PIE12-trimer as a strong clinical
candidate will allow D-peptide therapeutics to be evaluated in
vivo to determine if their theoretical advantages warrant a
prominent role as a new class of therapeutic agents.
FIG. 6. Effect of PIE7-dimer resistance mutations on PIE7-dimer,
PIE12-dimer, and PIE12-trimer potency. IC50s against wild-type (wt)
and PIE7-dimer-resistant (E560K/V570I) strain HXB2 pseudovirion
entry are shown. The C-peptide inhibitor C37 is included as a control.
Data represent the means from at least two independent experiments.
Error bars represent the standard errors of the means.
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Introduction 
 In 2012, an estimated 35.3 million individuals were living with HIV, a virus that 
has resulted in an estimated 36 million AIDS-related deaths since the beginning of the 
epidemic (UNAIDS report on the global AIDS epidemic 2013 fact sheet). 
 The advent of therapeutics targeting various stages of the viral lifecycle has 
dramatically improved the clinical outcome for those with access to treatment; however, 
resistance has been observed to develop against all classes of approved drugs (1).  This 
resistance is due to a highly error-prone viral reverse transcriptase, frequent 
recombination events, and rapid turnover of the virus (2, 3).  
 We recently reported the development of cost-effective and extremely potent D-
peptide HIV-1 entry inhibitors through mirror-image phage display (4-6) and the further 
improvement of potency to low pM levels by developing a crosslinking scaffold allowing 
for both trimerization of the peptide and attachment of a membrane targeting moiety that 
pre-positions the inhibitor at sites of viral entry (7). 
 These peptides act by tightly binding to a hydrophobic pocket at the base of the 
HIV-1 gp41 N-peptide trimeric coiled coil, and act by preventing the collapse of N- and 
C-peptide regions of gp41 to a 6-helix bundle structure, a structural transition required to 
bring the cellular and viral membranes in apposition for fusion (8) (see Fig. 2.1).   
 Because resistance against other entry inhibitors with similar modes of action 
(e.g., the FDA-approved Fuzeon) has been observed (9, 10), we were interested to 
evaluate the resistance profile of our lead candidates PIE12-trimer and cholesterolated 
PIE12-trimer (chol-PIE12-trimer).   
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 We previously reported a high barrier to resistance relative to other entry 
inhibitors (e.g., Fuzeon and previous generation D-peptides) for PIE12-trimer (5), which 
we hypothesize is the result of two distinctive features of our most potent D-peptides.  
First, while both Fuzeon and PIE12-trimer inhibit HIV entry by binding to the gp41 N-
peptide region, Fuzeon binds to an extended groove while PIE12-trimer binds to a 
separate deep hydrophobic pocket at the base of the groove (11).  This hydrophobic 
pocket is interesting in that it plays a key role in mediating viral entry (12) and the 
pocket-encoding region of the Env gene also contains the Rev response element (RRE), a 
structured RNA element required for nuclear export of viral RNA.  The hydrophobic 
pocket displays a remarkable degree of sequence conservation likely reflecting that 
mutations in this region must simultaneously preserve functionality of the fusion 
machinery and the RRE, thus restricting the range of potential resistance mutations and 
thereby raising the barrier to resistance against pocket-targeting entry inhibitors.   
 Second, during the optimization of previous generation D-peptide inhibitors, we 
noticed that as binding affinity for the pocket was improved via successive rounds of 
phage display, we reached a plateau in potency (6).  We proposed that this potency 
plateau is due to the transient nature of the gp41 pre-hairpin intermediate conformation 
targeted by these compounds.  Because the pre-hairpin intermediate conformation exists 
for a short time window, there is a point where association kinetics rather than binding 
affinity becomes the limiting factor for therapeutic potency.  Despite this plateau in 
potency, we continued to “over-engineer” the D-peptide binding affinity for the pocket.  
We reasoned that this excess of binding energy would sever the link between drug 
potency and affinity for the pocket such that a mutation that subtly weakens binding 
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affinity will not affect potency, and thus will not be provided with the selective advantage 
necessary to spread through the viral population.  We hypothesized that this “resistance 
capacitor” would prevent the development of drug resistance through pathways involving 
the incremental accumulation of subtle affinity-disrupting mutations. 
 While a high barrier to resistance was observed, we nonetheless reported the 
selection of strains resistant to PIE12-dimer and PIE12-trimer through viral passaging 
with escalating inhibitor concentrations (5).  Herein we extend the same methodology to 
cholesterolated PIE12-trimer (chol-PIE12-trimer). Furthermore, we comprehensively 
characterize the genotype of PIE12-dimer, PIE12-trimer, and chol-PIE12-trimer resistant 
viral populations through various sequencing methodologies, describe the biochemical 
and structural elucidation of a primary mechanism of resistance against PIE12-trimer and 
cholesterolated PIE12-trimer, discuss our progress towards characterizing the fitness and 
level of resistance of the resistant viral pools, and outline our strategy to overcome 
resistance. 
 
Materials and Methods 
Passaging studies 
PIE12-dimer and PIE12-trimer resistant viruses were acquired in a previous study 
(5).  chol-PIE12-trimer resistant viruses were generated starting from two different viral 
stocks.  Laboratory-adapted HIV-1 NL4-3 was passaged in the presence of escalating 
chol-PIE12-trimer concentrations as follows: 0.1 nM for 12 weeks, 0.4 nM for 4 weeks, 
and 1.6 nM for 5 weeks.  A second population of chol-PIE12-trimer resistant viruses was 
generated from PIE12-trimer resistant NL4-3 (that had been propagating in 320 nM 
PIE12-trimer) by passaging in the presence of escalating chol-PIE12-trimer 
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concentrations as follows: 30 nM for 12 weeks, 120 nM for 3 weeks, 480 nM for 4 
weeks, and 1000 nM for 5 weeks.   
 
Generation of envelope cDNA 
Viral RNA was isolated with the E.Z.N.A.® Viral RNA Kit (Omega Bio-Tek).  
cDNA for the envelope gene was generated using the SuperScript® III One-Step RT-
PCR System with Platinum® Taq High Fidelity (Invitrogen).  Primers were designed 
using Primer3Plus (13). 
 
Sanger sequencing of Env clones 
Sanger sequencing of viral envelope was conducted either as previously described 
(5) or as follows.  Envelope cDNA was cloned into various standard vectors using 
standard restriction enzyme cloning or TOPO® TA cloning (Life Technologies).  Vectors 
were transformed into E. coli and plated out on LB agar plates with appropriate antibiotic 
resistance.  Plasmids were isolated (GenElute™ Plasmid Miniprep Kit, Sigma) from 
cultures inoculated with individual colonies and were submitted to the DNA Sequencing 
Core Facility (University of Utah) for Sanger sequencing of the viral envelope. 
 
Deep sequencing and bioinformatic analysis 
Envelope cDNA from resistant populations was purified by SDS-PAGE, extracted 
(GenElute™ Gel Extraction Kit, Sigma), and submitted to the Microarray and Genomic 
Analysis Core Facility (University of Utah) for library preparation and sequencing.  
Barcoded samples were multiplexed onto a single lane and sequenced on an Illumina 
HiSeq 2000 (50 cycle single-end reads).  The raw sequencing reads in FASTQ format 
were mapped to nucleotides 6195-8826 from the HIV-1 vector pNL4-3 sequence 
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(GenBank: AF324493.2) using STAMPY (14).  A summary of base calls for each 
position of the reference sequence was generated by converting the alignment data to 
pileup format using the SAMtools:mpileup function (used -BQ0 and -d 2000000 options).  
Custom perl scrips (available  upon request) were used to convert base calls at each 
position from pileup format to a more intuitive table, and then to filter the data to display 
only those positions where deviations from the reference are present in the population 
above a user-defined threshold (10%). 
 
Peptide synthesis 
All synthetic peptides were acetylated at the N-terminus and amidated at the C-
terminus.  All reverse-phase HPLC (RP-HPLC) purifications were performed on a 
Waters C18 column (BEH X-Bridge, 19 x 250 mm, 10 µm, 300Å) with water/acetonitrile 
gradient in 0.1% TFA unless otherwise noted.  KG-PIE12 was synthesized by the 
University of Utah DNA/Peptide Core as described in (6) and purified via RP-HPLC on a 
Vydac C18 column (TP, 22 x 250 mm, 10 µm, 300Å).  PIE12-GK, PIE12-trimer, and 
cholesterol-PIE12-trimer were synthesized as previously described (5).  PIE12-Tide 
Fluor™2 was prepared by reacting PIE12-GK (~1.5 mM) with 1.5x excess of Tide 
Fluor™2 succinimidyl ester (AAT Bioquest) in dry DMAC with 250 mM 
triethanolamine.  The reaction was run overnight at room temp in the dark.  The reaction 
was quenched by the addition of AcOH to 5% and then purified via RP-HPLC.  SelMet-
IQN17-Q577R and HIV C34 were synthesized on a PS3 peptide synthesizer (Protein 
Technologies, Inc.) at 80 umol scale on NovaPEG Rink Amide LL resin (Novabiochem) 
and Rink Amide AM resin LL (Novabiochem), respectively, via Fmoc-SPPS and were 
purified by RP-HPLC. 
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Recombinant protein production 
Cys-Gly-Gly-Asp-IZN36 (derived from HXB2 strain) cloned into pET14b behind 
the His tag and thrombin cleavage site had been prepared previously (6).  A Q577R 
mutant version was generated via site-directed mutagenesis using the QuikChange® 
protocol (Stratagene).  Protein expression was performed in BL21 (DE3) cells (Novagen) 
following Studier’s autoinduction protocol (15).  Cultures were grown in Fernbach flasks 
shaking at 150 RPM overnight at 37ºC.  Cells were pelleted by centrifugation, 
resuspended in 20 mM sodium phosphate pH 8.0, 300 mM NaCl, 10 mM Imidazole, and 
frozen at -80ºC until further use.  Cells were disrupted by sonication and centrifuged for 
20 minutes at 20,000xg (4ºC).  The pellet (containing IZN36 in inclusion bodies) was 
solubilized in 20 mM sodium phosphate pH 8.0, 300 mM NaCl, 10 mM Imidazole, 6 M 
GuHCl, and sonicated again.  The sample was clarified by centrifugation (20 min, 
20,000xg) and applied to His-Select Ni-affinity resin (Sigma).  Following thorough 
washing, the protein was eluted in 20 mM sodium phosphate pH 8.0, 300 mM NaCl, 250 
mM Imidazole, 6 M GuHCl.  Samples were dialyzed into H2O with 0.1% TFA and 
purified via RP-HPLC on a Waters C18 column (BEH X-Bridge, 19 x 250 mm,10 µm, 
300Å) with water/acetonitrile gradient in 0.1% TFA and lyophilized.  The cysteine 
residues of these constructs were biotinylated for SPR.  Reactions were carried out in 
PBS pH 7.0 with ~1-2mg/mL protein and a 15x molar excess of Biotin-dPEG®3-MAL 
(Quanta BioDesign) at room temp for 1 hr.  Proteins were purified via RP-HPLC as 
above.  Removal of the His tag was carried out in PBS buffer pH 6.3 with 10 uM heparin 
at a protein concentration of ~0.8mg/mL with 1 unit Thrombin protease (GE Healthcare) 
 35 
per mg of protein.  The cleavage reaction was incubated at 37ºC with agitation for 44 hrs 
followed by RP-HPLC as above.   
 
Protein interaction analysis 
Protein interaction analysis was carried out on a Biacore 3000.  Streptavidin 
(Pierce) was immobilized on CM5 chips (GE Healthcare) using the Amine Coupling Kit 
(GE Healthcare) following a standard coupling protocol (16).  Biotinylated IZN36 
constructs (WT and Q577R mutant) were captured on the surface to a density of between 
100-200 RUs.  IZN36 stocks for target loading (~50 nM) were prepared in running buffer 
in the presence of 1.2x molar excess of HIV C34 (we found that loading IZN36 in the 
presence of C34 results in better behaved surfaces).  C34 was removed by surface 
regeneration with 0.1% SDS injections.  A free, Streptavidin-derivatized surface served 
as a blank.  Analyses were performed at 25ºC in sterile filtered and degassed Gibco® 
PBS buffer pH 7.4 (Invitrogen) supplemented with 0.005% P20 and 1mg/mL BSA at a 
flow rate of 50 μL/min.  Stock solutions of PIE12GK were prepared at 50 μM in running 
buffer from which samples in the concentration series were generated by serial dilution.  
Injections were performed for 1 min using KINJECT.  Dissociation was monitored for 2 
min, followed by a 20 μL injection (QUICKINJECT) of running buffer followed by 
EXTRACLEAN.  Sensorgrams were processed using Scrubber2 (BioLogic Software), 
and data were analyzed with Prism 5.0 (GraphPad Software).  The equilibrium binding 
data were fit using the built-in saturation binding model (One site -- Specific binding), 
normalized to Bmax, and replotted as concentration of analyte vs. % capacity.   
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Crystallography 
KG-PIE12 was crystallized in complex with IQN17-Q577R (1:1.1 IQN17:KG-
PIE12, 10 mg/mL total in water) under a variety of conditions. Crystal trays were 
prepared in Intelli-Plate 96-3 well plates (Art Robbins Instruments) using a Crystal 
Phoenix (Art Robbins Instruments). In each case, the reservoir (60 μL) consisted of a 
commercially available crystallization screen and the crystallization drop (0.6 μL) 
contained either 2:1, 1:1, or 1:2 protein:reservoir condition. Crystals typically grew in 
less than 10 days by sitting-drop vapor diffusion.  IQN17-Q577R crystals were grown at 
21°C in Hampton Research condition SaltRx HT B4 (1.8 M ammonium citrate dibasic, 
0.1 M sodium acetate trihydrate, pH 4.6).  Crystals were mounted in a nylon loop and 
either directly cryocooled by plunging into liquid nitrogen or cryocooled following a 20 s 
immersion in 20 μL crystallization buffer with 20% added glycerol.  Crystals were 
maintained at 100 K during data collection. Data collection was performed at the 
Stanford Synchrotron Radiation Lightsource (SSRL).  Data were processed using 
DENZO and SCALEPACK (17).  The IQN17-Q577R/PIE12 structure was determined by 
molecular replacement using PHASER (18) with PIE12-IQN17 (pdb structure 3L37) as 
the search model. The model was rebuilt using O (19) and COOT (20) and refined against 
a maximum-likelihood target function using PHENIX (21). The structure was checked 
using the MolProbity program (22). See Fig. 4.1 for crystallographic data. 
 
Infectivity of the polyclonal resistant pools 
Infectivity of polyclonal resistant pools was measured using TZM-BL cells 
following standard protocols (our collaborator (MJR) is currently preparing a detailed 
protocol for the publication of this work). 
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Results 
Passaging 
 We previously reported the development of HIV-1 populations resistant to PIE12-
dimer and PIE12-trimer derived from a parental laboratory-adapted NL4-3 strain by 
passaging the virus in the presence of escalating concentrations of inhibitor; acquiring 
PIE12-dimer resistant virus propagating in 1280 nM PIE12-dimer (~85x IC50 of parental 
strain) and PIE12-trimer resistant virus propagating in 320 nM PIE12-trimer (~750x IC50 
of parental strain) (5).  Similar passaging studies were performed with the inhibitor chol-
PIE12-trimer beginning with either naive virus (laboratory-adapted HIV-1 NL4-3) or 
PIE12-trimer resistant virus.  Starting with naive NL4-3, we were able to acquire a virus 
able to stably propagate in the presence of 1.6 nM chol-PIE12-trimer (~80x the IC50 of 
the parental strain) after 21 weeks of passaging.  By starting the experiment with a 
resistant strain of NL4-3 able to passage in the presence of 320 nM PIE12-trimer (well 1), 
we were able to acquire a virus able to propagate in the presence of 1000 nM chol-PIE12-
trimer (~50,000x the IC50 of the parental strain) after  24 weeks of passaging.   
 
Inhibition of resistant pools 
 In order to characterize the degree of resistance acquired during the passaging, 
inhibition assays were performed on the polyclonal resistant viral pools to calculate the 
new IC50 values.  PIE12-dimer resistant virus, a series of archived viruses from the 
PIE12-trimer resistance passaging (taken from different time points when the virus was 
passaging at different concentrations of inhibitor - 10, 40, 80, 320 nM), and both chol-
PIE12-trimer resistant populations (one generated starting from naive NL4-3 with the 
other starting from PIE12-trimer resistant virus (propagating at 320 nM PIE12-trimer, 
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well 1)), were all assayed.  While the initial data presented in Fig. 4.2 are preliminary 
(and will be repeated with more precision), it is clear that high levels of resistance were 
acquired for all inhibitors.   
 Several interesting observations can be made from the inhibition data. 1) While 
PIE12-dimer resistance does impact PIE12-trimer inhibition, PIE12-trimer is still able to 
inhibit the PIE12-dimer resistant population at low nM concentrations; however, PIE12-
trimer resistance completely abolishes the potency of PIE12-dimer.  This suggests two 
separate resistance mechanisms, with the PIE12-trimer resistance mechanism being more 
severe.  2) Cross-resistance to C37 (an entry inhibitor that works through a similar 
mechanism) was only observed in one population (PIE12-dimer resistant).  This suggests 
that while a more general resistance mechanism is at play (e.g., altered fusion kinetics) in 
the PIE12-dimer resistant virus, a more specific mechanism is being utilized by PIE12-
trimer and chol-PIE12-trimer resistant viruses that does not necessarily affect other entry 
inhibitors targeting the N-peptide region.  3) While chol-PIE12-trimer resistant virus 
(started from the naive NL4-3 parental strain) displays similar resistance against both 
chol-PIE12-trimer and PIE12-trimer compared to the PIE12-trimer resistant viruses, the 
chol-PIE12-trimer virus (started from the PIE12-trimer resistant virus (well 1)) manifests 
a marked increase in resistance to both PIE12-trimer and chol-PIE12-trimer.   
 
Sequencing 
 To thoroughly characterize the genetic basis of resistance, viral RNA was isolated 
from PIE12-trimer, PIE12-dimer, and chol-PIE12-trimer resistant viral pools as well as 
RNA from a control virus that had been propagated in the absence of any inhibitors.  The 
isolated RNA was used to generate corresponding cDNA of the Env gene, which was 
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either cloned into a vector for sequencing of full-length Env clones, or submitted for deep 
sequencing.  These two sequencing strategies were pursued in parallel to leverage the 
relative strengths of each method.   
 The advantage of sequencing the entire Env gene from single clones via Sanger 
sequencing is that linkage information from mutations that reside anywhere in the 
genome is preserved; however, the drawback is that due to the time, labor, and cost 
involved in acquiring sequences of Env clones in this manner, it is relatively low 
throughput.  While deep sequencing is not able to yield long-range linkage information 
between potential linked mutations (as the reads are very short), it does give a remarkable 
depth of coverage of Env genes from a resistant population (we achieved an average 
depth of coverage of ~260,000x for each position of Env for each sample submitted), 
giving a comprehensive view of genetic space.   
 We submitted Env cDNA from laboratory-adapted HIV-1 NL4-3 (to serve as a 
control to help distinguish between laboratory adaptations and resistance mutations in our 
resistant populations); the PIE12-dimer resistant virus able to propagate in the presence 
of 1280 nM PIE12-dimer; the series of archived viruses from the PIE12-trimer passaging 
study from different time points while it was passaging at various levels of PIE12-trimer 
(10, 40, 80, and 320 nM PIE12-trimer); another PIE12-trimer resistant virus propagating 
at 320 nM inhibitor from an independent passaging experiment (denoted as well 2 to 
distinguish it from the 320 nM sample from the aforementioned series (which is denoted 
well 1)); the chol-PIE12-trimer resistant virus (started from naive NL4-3) able to 
propagate at 1.6 nM chol-PIE12-trimer; and the chol-PIE12-trimer resistant virus (started 
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from PIE12-trimer resistant virus propagating at 320 nM PIE12-trimer) able to propagate 
at 1000 nM chol-PIE12-trimer. 
 Sanger sequencing data on a total of 13 PIE12-trimer resistant clones (five clones 
from virus propagating at 320 nM in well 1, and eight clones from the virus propagating 
at 320 nM in well 2) was also performed, and the data are in excellent agreement with the 
deep sequencing analysis (data not shown).    
 218 positions in the sequenced region across all resistant populations (PIE12-
dimer, PIE12-trimer, chol-PIE12-trimer) were identified in the deep sequencing data 
where the sum of all nonreference calls (including insertions and deletions) was greater 
than 10% of the total calls.  For preliminary analysis, we reasoned that 10% should be a 
high enough threshold that most of the noise due to genetic drift will be filtered out, but 
low enough to catch minor variations in the population that could give rise to resistance.   
 Mutations have been further filtered to include only those mutations that occur at 
high prevalence in a population (≥50%), are not silent (unless in RRE where a silent 
mutation could affect RNA structure), occur at any frequency at an interesting location in 
Env, or occur at any frequency when present at the same position across multiple 
independent samples, resulting in a table of 71 total positions mutated across all 
sequenced samples (28, PIE12-dimer; 13, PIE12-trimer (10 nM); 14, PIE12-trimer (40 
nM); 15, PIE12-trimer (80 nM); 21, PIE12-trimer (320 nM, well 2); 20, PIE12-trimer 
(320 nM, well 1); 26, chol-PIE12-trimer (started from PIE12-trimer resistant virus); 30, 
chol-PIE12-trimer (started from naive NL4-3)).   
 A few interesting features stand out that might hint at important resistance 
mutations (or important compensatory mutations associated with resistance mutations).   
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 There are two prominent in-frame deletions (Δ509-520/Δ512-523 in the V1/V2 
loop of gp120, and Δ1206-1220 in the V4 loop of gp120) that occur in all of the resistant 
populations except PIE12-dimer (lacks the V1/V2 loop deletion) and the 10 nM PIE12-
trimer (lacks the V4 loop deletion).  The V1/V2 loop deletion occurs in all populations 
with high PIE12-trimer resistance, indicating that it is likely causing or is associated with 
(i.e., compensatory mutation) high PIE12-trimer resistance.  The V4 loop mutation 
occurs at a prevalence of ~50% in populations that contain it; however, the region deleted 
is immediately adjacent to an identical stretch of sequence.  Thus, it is possible that the 
deletion is present at ~100% in the populations that contain it, and that the reported 50% 
is a bioinformatic artifact.  Future analysis will determine if this is the case.    
 There are many mutations in residues at glycosylation sites (canonical NXT/S 
sites) that will modify the glycosylation pattern of Env.  These modifications could 
potentially affect its structure or activity (e.g., fusion kinetics) in such a way that fosters 
resistance.   
 There are a few mutations in the CD4-binding interface that could affect how Env 
interacts with its receptor.   
 The mutation of residue Q577 (to R, N, or K) in all of the PIE12-trimer and chol-
PIE12-trimer resistant populations is of special interest.  Previous preliminary sequence 
analysis conducted on a limited number of clones from a PIE12-trimer resistant 
population focusing on the N-peptide region of Env identified the presence of the Q577R 
mutation in the pocket region, a residue that directly interacts with the PIE12 peptide (5).  
Subsequent work has shown that Q577R impacts the potency of both PIE12-trimer (IC50 
changes from 0.72 to > 3 μM) and chol-PIE12-trimer (IC50 changes from 0.013 to 10.1 
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nM) when incorporated into HXB2 pseudovirions (7).  A similar effect has been observed 
for the Q577K mutation (data not shown).  This pseudovirion data, taken with the above 
polyclonal inhibition data, suggest that Q577R is a key determinant of resistant in PIE12-
trimer and chol-PIE12-trimer populations. 
 Interestingly, the Q577R mutation was not seen in PIE12-dimer resistant 
populations, where there is a different mutation in the binding site (I580L).  Because this 
mutation is conservative, is not directly involved in the PIE12/pocket interaction, and has 
been shown to have no effect on potency of PIE12-trimer or chol-PIE12-trimer (data not 
shown), its role in PIE12-dimer resistance appears unlikely, but awaits further 
examination.  It appears that the main resistance mutations in the PIE12-dimer resistant 
population lie far from the binding pocket, a phenomenon not unheard of as mutations 
outside the binding site have been associated with reduced susceptibility to entry 
inhibitors (2). 
 Because the chol-PIE12-trimer resistant population (started from naive NL4-3) 
displays a similar level of resistance to PIE12-trimer and chol-PIE12-trimer as both the 
PIE12-trimer resistant populations and the HXB2 Q577R pseudovirions (mentioned 
above), and because this chol-PIE12-trimer resistant population contains ~100% Q577R, 
it is probable that Q577R alone accounts for the majority of the chol-PIE12-trimer 
resistance phenotype in this population.   
 Because resistance against chol-PIE12-trimer increased (IC50 changed from ~10 
nM to > 100 nM) in the passaging studies started with PIE12-trimer resistant virus (320 
nM, well 1), and because there are relatively few sequence differences between these two 
populations, it is possible to narrow the mutations responsible for this increase in 
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resistance against chol-PIE12-trimer by comparing the sequences and noting mutations 
unique to the chol-PIE12-trimer resistant population.  13 differences occur in the filtered 
data set (F175L, V200E, S306R, M326L, G354E, S387T, N460I, H643Y, N674T, 
P727L, S810R, V829I, and V832L), two of which are at glycosylation sites (S387T and 
N674T), one is in the C-peptide region (H643Y), and one (M326L) is in the V3 loop and 
has been implicated in being involved in the gp120/co-receptor interface (23). 
 
Protein interaction analysis of Q577R 
 The crystal structure of PIE12 in complex with an N-peptide pocket mimic 
indicates that Q577 makes important hydrogen bond contacts with residues in PIE12 
(Glu7 and Trp10) (5), and their disruption via the Q577R mutation is likely to weaken the 
binding affinity of the D-peptide, resulting in the resistance seen in the PIE12-trimer and 
chol-PIE12-trimer resistant populations and the previously mentioned HXB2 
pseudovirions bearing only the Q577R mutation (see discussion above). To determine the 
impact of the Q577R on PIE12 binding affinity, the mutation was incorporated into an N-
peptide mimic (IZN36 (24)) and the interaction was analyzed via surface plasmon 
resonance analysis (SPR).  The mutation results in a dramatic weakening of the 
interaction (Fig. 4.3).  Furthermore, because our inhibitor is trimeric, we expect the 
diminished binding affinity seen for the monomer to have a more pronounced effect on 
the observed binding affinity of PIE12-trimer.  Similar results were obtained through 
fluorescence polarization using a fluorescently labeled PIE12 peptide (data not shown).  
These data, coupled with the sequencing and inhibition data for the polyclonal resistant 
pools (and the HXB2 Q577R pseudovirion data), indicates that Q577R (and likely 
Q577N and Q577K seen in the deep sequencing data) is a major cause of resistance 
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against PIE12-trimer and chol-PIE12-trimer.  This also likely explains the high level of 
PIE12-trimer resistance previously seen in Group O strains, as the isolates we have 
assayed contain Q577R (as well as a number of other pocket mutations (5)). 
 
Crystallographic analysis of Q577R 
 To further interrogate the effect of Q577R on the PIE12/pocket interaction, 
monomeric PIE12 was crystallized in complex with an HIV-1 N-peptide pocket mimic 
(IQN17 (24)) bearing the Q577R mutation.  An overlay of the region around position 577 
of the acquired structure of PIE12/IQN17 (Q577R) with a structure of PIE12/IQN17 (wt)  
(pdb structure 3L37) is presented along with crystallographic statistics in Fig. 4.1.  As 
expected, the Q577R mutation disrupts hydrogen bonds between Q577 and two PIE12 
residues (Glu7 and Trp10).  There is also a repositioning of two adjacent residues 
(residue Glu9 in PIE12 and L561 in IQN17).   
 
Discussion and Future Directions 
 In summary, by applying genomic, biophysical, virological, and structural 
methods, we have determined that Q577R is a major cause of resistance to PIE12-
containing D-peptide entry inhibitors.  One remaining question is why Q577R is so 
difficult to acquire (i.e., why do these peptides have such a high barrier to resistance if 
one mutation can dramatically diminish their potency?).  One possibility is that while 
Q577R is sufficient to impart significant resistance, it might negatively impact fitness.  
Thus, in order for Q577R to establish itself, it might require compensatory mutations to 
repair the fitness defect.  In line with this hypothesis, while preliminary fitness data show 
no obvious signs of a serious growth defect in any of the resistant populations (data not 
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shown), a prior mutagenesis study on the gp41 N-peptide demonstrated that while 
pseudovirions can be generated with the Q577R mutation, and that Env in packaged and 
processed to wt levels, the virions exhibit a severe infectivity defect (infectivity < 5% of 
wt) (25).  Studies are already underway to characterize the fitness of the polyclonal 
resistant pools, as well as the Q577R/N/K mutations alone in a wt background.   If a 
fitness defect is observed, we will determine the compensatory mutations that restore 
fitness by either adding more mutations into the wt background, or starting with an Env 
clone from a resistant population containing the compensatory mutations and subtracting 
them out until a fitness defect is observed.   
 We are also interested in determining the mutations that result in PIE12-dimer and 
high chol-PIE12-trimer resistance, and if anything other than Q577R/N/K contributes to 
PIE12-trimer resistance.  To this end we are currently generating Env expression 
plasmids containing Env clones from the resistant populations.  For Env sequences from 
the PIE12-trimer resistant populations, we have reset Q577R back to wt (to see if any 
other mutations contribute to resistance).  By generating chimeric Env constructs (e.g., wt 
gp120, mutant gp41, or vice versa) and then narrowing down from there, we hope to 
determine mutations responsible for resistance. 
 Ultimately we are interested in not simply understanding resistance, but 
overcoming it.  To this end, we have already cloned Q577R into a target for mirror-image 
phage display, and efforts are underway to discover novel D-peptide entry inhibitors that 
bind with high affinity to the mutant pocket, or that bind well to both the mutant and wt 
pocket.   
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A) 
 
 
 
B) 
Crystallographic Data and Refinement Statistics 
SelMet-IQN17 Q577R / KG-PIE12 
Space Group R3 
Contents per asymmetric unit 1 IQN monomer, 1 D-peptide 
Resolution 1.3 Å 
Rcrys1 0.197 
Rfree2 0.225 
 
1 Rcrys=∑||Fo|-|Fc|/∑|Fo|  
2 Rfree is the same as Rcrys calculated with a randomly selected test set of reflection that 
were never used in refinement. 
 
Figure 4.1. Crystallographic analysis of Q577R mutation. A) Overlay of crystal 
structures of PIE12 binding to the wt pocket (yellow) and a mutant (Q577R) pocket 
(turquoise) showing the disruption of important hydrogen bonding interactions mediated 
by residue 577.  B) Data and Refinement statistics. 
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 PIE12-dimer 
(nM) 
PIE12-trimer 
(nM) 
chol-PIE12-trimer 
(nM) 
C37 
(nM) 
control NL4-3 15 0.43 0.02 3.4 
PIE12-dimer resistant (1280 nM) 860 52 - 30 
PIE12-trimer resistant (40 nM) >1,000 ~2000 ~10 8.5 
PIE12-trimer resistant (80 nM) - ~2000 ~10 4 
PIE12-trimer resistant (320 nM) - ~2000 ~10 5 
chol-PIE12-trimer resistant (from naive) - ~2000 ~10 7.5 
chol-PIE12-trimer resistant  
(from PIE12-trimer resistant virus) 
- >> 1000 >100 6.9 
 
Figure 4.2. Inhibitory data for polyclonal resistant pools. Preliminary IC50 values for 
polyclonal resistant pools.  Yellow indicates a modest level of resistance (< 10x change 
in IC50), light red indicates high level resistance (> 50x change in IC50), and dark red 
indicates an extreme level of resistance (> 2,000x change in IC50) 
 
 
 
 
Figure 4.3. Protein interaction analysis of Q577R mutation. Equilibrium binding data 
(in triplicate) for interaction between immobilized IZN36 (wt or Q577R) and PIE12 
monomer.   
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Introduction 
 
The filoviruses Ebola virus (EboV) and Marburg virus (MarV) are enveloped, 
negative-strand RNA viruses that cause severe hemorrhagic fever (1). Since their 
identification almost 50 years ago, there have been over 20 reported natural filovirus 
outbreaks and several accidental laboratory exposures with an overall mortality rate of 
70%, including 4 outbreaks in 2012 (2). Currently no vaccines or therapeutics are FDA 
approved. Because of ease of transmission, high mortality, and potential for a severe 
impact on public health, the CDC places filoviruses in its highest category of potential 
agents of bioterrorism (3). There is a vital need for a broad spectrum filovirus 
preventative and/or therapeutic to protect against future natural, accidental, or deliberate 
outbreaks. 
Filovirus entry into host cells is mediated by the viral surface glycoprotein (GP), a 
class I fusion protein. GP is comprised of two disulfide-linked subunits, one surface 
exposed (GP1) and one embedded in the viral membrane (GP2) (4, 5). Following binding 
to host cells via cell surface attachment factors, the virus is endocytosed. Endosomal 
cysteine proteases, such as cathepsins, remove much of GP1 via cleavage, exposing the 
binding site for the receptor (the endosomally located NPC1) (6-10). At this point, the 
fusion mechanism is thought to mimic that used by other well-characterized viral class I 
fusion proteins, such as HIV-1 and influenza (11-13) (Fig. 5.1). GP2 forms a transient 
conformation (“pre-hairpin intermediate”) embedded in both virus (via the 
transmembrane domain) and host cell (via the fusion loop) membranes. This pre-hairpin 
intermediate exposes a trimeric coiled coil formed by the N-terminal region (N-trimer) 
and the unstructured C-terminal region (C-peptide). Slow collapse of the intermediate 
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into a highly stable trimer-of-hairpins structure, with the C-peptide binding into the 
grooves on the N-trimer, juxtaposes the virus and cell membranes, leading to membrane 
fusion. 
In the case of HIV-1, the pre-hairpin intermediate has been exploited to develop 
highly potent viral entry inhibitors (14-16) (Fig. 5.1). Essentially, peptides and proteins 
that bind with high affinity to either the N-trimer or C-peptide regions prevent formation 
of the 6-helix bundle in a dominant-negative manner, thereby halting viral entry (as 
reviewed (17)). The most potent of the HIV entry inhibitors, chol-PIE12-trimer, binds to 
the highly conserved hydrophobic pockets of the HIV N-trimer and inhibits HIV entry 
with picomolar potency (14).  
Chol-PIE12-trimer is a D-peptide now under preclinical development for HIV 
treatment and prevention. D-peptides have several important potential advantages as drug 
candidates (as reviewed (18)). As peptides, they are capable of preventing large 
protein/protein interactions, something that is generally not possible for small molecules. 
This gives them the potential of being highly potent (strong clinical efficacy) and specific 
(low toxicity). In addition, since they are resistant to protease degradation (19), D-
peptides should enjoy a long in vivo half-life and reduced immunogenicity (20). 
Specifically for filovirus entry inhibition, resistance to endosomal proteases is highly 
advantageous. 
Since filoviruses and HIV-1 share a similar mechanism of entry, they are likely 
vulnerable to similar inhibition strategies of targeting the pre-hairpin intermediate. Our 
ultimate goal is to mimic our HIV-1 entry inhibitor discovery program (14-16, 21) and 
identify D-peptides that target the filovirus N-trimer and inhibit filovirus entry. The N-
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trimer is a promising target as it is highly conserved among filoviruses. Indeed, although 
the overall sequence identity of GP in the EboV strains pathogenic to humans is only 
42%, the N-peptide region is 92% identical (and all changes are conservative). 
Comparing EboV to MarV, the N-trimer is 67% identical, compared to 26% for GP as a 
whole. Here, we describe the foundational steps of this development program. 
Specifically, we have developed and characterized peptide mimics of filovirus N-trimers, 
validated their use as drug discovery tools, and explored specific conditions that will be 
applied to our mirror-image phage display (22) discovery process. In addition, using one 
of our N-trimers as an inhibitor itself (to target the C-peptide region of the pre-hairpin 
intermediate), we have demonstrated the vulnerability of the pre-hairpin intermediate.  
 
Results and Discussion 
N-trimer mimic design 
 Based on our previous HIV-1 work (21, 23), we set out to design soluble peptide 
mimics of the N-trimer region of the EboV pre-hairpin intermediate by fusing stable, 
soluble designed trimeric coiled coils to the N-trimer sequence. As with HIV-1, the 
filovirus N-trimers aggregate when produced in isolation. Unlike HIV-1, the EboV N-
trimer does not possess an obvious “pocket” ideal for drug targeting. Therefore, we were 
interested in presenting the entire N-trimer groove as well as a smaller, more conserved 
region of the N-trimer to provide flexibility in targets and drug screening. Our initial 
designs, in which we fused the coiled coil IZm(23) N-terminal to N-trimer segments of 29 
and 39 amino acids, were highly aggregated as determined by analytical 
ultracentrifugation (AUC) sedimentation equilibrium experiments (data not shown). To 
overcome this problem, we fused an additional trimeric coiled coil, GCN4-pIQI’ (IQ) (24) 
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to the C-terminus of the EboV N-trimer. The resulting peptide, eboIZN39IQ presents the 
full EboV N-trimer (determined from available 6-helix bundle crystal structures (25, 26)) 
as a trimeric coiled coil, as shown by circular dichroism (CD) (Fig. 5.2a) and AUC 
(Table 5.1). eboIZN39IQ is highly stable, as it has almost identical CD spectra at 25 °C, 
37 °C, and 50 °C (Table 5.1). The ultimate goal for a filovirus N-trimer mimic is to use it 
as a target in drug screening, specifically mirror-image phage display (22), to identify 
inhibitors of filovirus entry. Since these inhibitors will have to bind to the virus in the 
endosome, all of the biophysical analyses were performed at pH 5.8 to mimic the low pH 
of the endosome.   
 To produce a smaller target that presents a discrete, 100% identical region of the 
N-trimer (across all EboV strains, Fig. 5.3), IZm was fused to the N-terminal 21 amino 
acids of the N-trimer, resulting in eboIZN21. Circular dichroism indicates eboIZN21 is a 
coiled-coil (Fig. 5.2b), and AUC studies show it is largely trimeric with a slight tendency 
to form higher order aggregates (Table 5.1). As seen with eboIZN39IQ, eboIZN21 is 
highly stable, showing almost identical CD signatures at 25 °C, 37 °C, and 50 °C (Table 
5.1). We also attempted to produce mimics presenting the middle and C-terminal portions 
of the N-trimer, but unfortunately, they had difficult solubility problems (data not shown) 
and were not studied further.  
 As negative controls for binding studies and drug discovery efforts, we produced 
mutant N-trimer mimics aimed at abolishing the C-peptide binding site. Specifically, 
three alanines that are found along the C-peptide binding groove were mutated to 
aspartate, introducing charges along the groove. The resulting peptides are termed 
eboIZN39IQ(D3) and eboIZN21(D2). Using CD and AUC, we confirmed that these 
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mutants maintained the highly stable coiled-coil structure and trimeric nature of their 
wild type counterparts (Fig. 5.2 and Table 5.1). 
C-peptide binding characterization 
 To validate that eboIZN39IQ presents the native conformation of the N-trimer 
found in the pre-hairpin intermediate, we characterized the binding of its native ligand as 
seen in the postfusion 6-helix bundle conformation, the Ebola C-peptide (eboC37). 
Surface plasmon resonance (SPR) analysis (ProteOn, Bio-Rad) of the full-length 
interaction of eboC37 binding to eboIZN39IQ shows an affinity constant of 7.5 nM (Fig. 
5.4), with no binding to the D3 negative control. This tight binding affinity is the same 
magnitude as the HIV-1 N-trimer/C-peptide interaction (16), and is strongly indicative of 
eboIZN39IQ presenting a native N-trimer. A shortened C-peptide (eboC24) missing the 
13 N-terminal residues of eboC37 binds to eboIZN39IQ with an affinity constant of ~500 
nM and no binding to the D3 negative control (data not shown). 
 
Phage display target validation 
 The ultimate goal for these N-trimer mimics is to use them as targets in mirror-
image phage display to identify D-peptide ligands to serve as drug development leads. To 
validate them as discovery targets, in a series of phage clone binding assays we analyzed 
their ability to bind to their native binding partners, eboC37 and eboC24, in the context of 
phage. Importantly, these experiments were designed not just to verify ligand binding but 
to define the best conditions for future phage display discovery efforts. 
 Phage display selections can be conducted in two formats, solid-phase and 
solution-phase. In solid-phase selections, the target is bound to a solid support (in this 
case, biotinylated Ebola N-trimer mimic is attached to streptavidin-coated magnetic 
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beads), and then the phage are incubated with the target on that solid support, typically 
until equilibrium is reached. Since common phage display libraries are multivalent 
(multiple copies of the library peptide are expressed on the surface of the phage, due to 
fusion to multicopy coat proteins), avidity effects increase the apparent binding constant 
of the library peptides. This avidity-induced affinity boost is beneficial when screening 
naïve phage libraries, where initial binders typically have low target affinities. In 
solution-phase, the target and phage are incubated in solution, and avidity effects are 
minimized. Then, the bound complexes are captured through a brief interaction with a 
solid support (again, in this case, through a biotinylated target and streptavidin beads). At 
the same concentration of target, solution-phase is typically a more stringent condition 
than solid-phase. The stringency of solution-phase is useful when screening consensus 
libraries, where tight binders must be distinguished from a background of specific 
binders. 
 In a solution-phase clonal phage ELISA format carried out at pH 5.8 to mimic the 
endosomal environment and with biotinylated eboIZN39IQ as the target, both eboC37 
and eboC24 clonal phage bound to target significantly over background (both empty 
beads as well as beads with our negative control, eboIZN39IQ(D3)), validating 
eboIZN39IQ as a potential phage display target (Fig. 5.5). In this format, both C-peptide 
clones bound at similar levels, although eboC37 had much greater background binding to 
both negative controls. Interestingly, a relatively high level of nonspecific phage binding 
to the eboIZN39IQ target was also observed, as indicated by the M13KE empty phage 
binding (i.e., no peptide displayed). 
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 Using eboIZN21 as a target in a solid-phase eboC24 clonal phage ELISA, binding 
at up to two orders of magnitude over background was seen. Also, a very low level of 
M13KE empty phage binding was observed (Fig. 5.6).  
 To further investigate the phage background binding to eboIZN39IQ, and to 
compare the two targets, we analyzed empty M13KE phage binding to both targets under 
varying conditions (Fig. 5.7). In both solid- and solution-phase formats, M13KE phage 
binding is significantly higher for eboIZN39IQ beads than blank beads, although the 
difference is lower for solution phase. For the eboIZN21 target, there is no background 
binding problem, where binding of M13KE phage is similar to both target and blank 
beads in solid and solution phase. Under more stringent conditions (solution phase, 100 
nM target) the M13KE background binding to eboIZN39IQ is minimized, and an affinity 
difference for eboC24 binding to eboIZN39IQ vs. eboIZN21 can be seen, indicating the 
importance of stringency conditions in performing phage display selections. This affinity 
difference is expected, as the 6-helix bundle structures (25, 26) show the binding site of 
eboC24 extending past the C-terminus of N21.   
Importantly, the first step of a phage display discovery process is to screen a naïve 
phage display library for binding to the desired target. In such a first selection, where the 
library diversity only partially samples the large potential sequence space (for example, a 
naïve 12-mer library has >1015 possible sequences (20n), whereas the typical diversity of 
the phage display library is 1010), the best binders identified are modest, typically with 
low to mid-micromolar affinities. Therefore, the selection pressure during the phage 
panning must also be modest. Standard naïve phage display starting conditions are 10 µM 
target presented on solid-phase (e.g., (21)). As illustrated in Fig. 5.7, M13KE binding to 
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eboIZN39IQ is nearly saturated at this condition, and therefore, it would not be possible 
to identify any binding over background. Under the same conditions, the eboIZN21 
background binding is three orders of magnitude lower and equal to blank bead binding, 
ideal starting conditions for naïve phage display. Therefore, eboIZN21 is an optimized 
target for our mirror-image phage display discovery process. Additionally, the eboC24-
phage can serve as an important positive control to use during naïve phage display to 
validate the conditions used to capture weak, but specific binders. Importantly, in 
addition to having ideal behavior in phage display, the N21 region is identical across all 
EboV strains and highly conserved among filoviruses (95% conserved) (Fig. 5.3).  
In addition to serving as a target for identifying D-peptide inhibitors, the filovirus 
N-trimer mimics (in L) may also be successful targets for antibody phage display and/or 
as immunogens to elicit a broadly neutralizing antibody that targets this highly conserved 
region. Such a strategy was successful for identifying a broadly reactive HIV-1 antibody, 
D5 (27). Finally, they could be a useful cell biological tool, as labeled N-trimers could be 
used in cell culture experiments to track the appearance of the pre-hairpin intermediate 
during the viral entry event.   
 
Target synthesis in D 
 Mirror-image phage display is a clever modification of traditional phage display 
(21, 22). In traditional phage display, a library of phage, each with a unique peptide 
displayed on its surface, is screened against a target. The phage links phenotype (target 
binding) to genotype (the DNA encoding the surface peptide is in the genome). In mirror-
image phage display, the screening target is made by standard chemical synthesis with D-
amino acids and therefore forms the mirror-image structure of the natural L-target. Phage 
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display using the D-target is performed, and identified L-peptides that bind the D-target 
are then chemically synthesized with D-amino acids. By the law of symmetry, these D-
peptides bind the natural L-target. Therefore, unlike with traditional phage display, 
mirror-image phage display targets are limited in size to those that can be chemically 
synthesized. Importantly, even though the length of eboIZN39IQ is beyond the scope of 
standard solid-phase peptide synthesis (SPPS) techniques, modern chemoselective 
ligation techniques (28) allow for its assembly from multiple peptide fragments. 
At a length of 48 amino acids, D-eboIZN21 is readily synthesized through standard 
SPPS techniques. D-eboIZN39IQ, at 101 amino acids, was assembled using native 
chemical ligation (29) and metal-free desulfurization (30). D-eboIZN39IQ was assembled 
from three synthetic fragments, whereas D-eboIZN39IQ(D3) was assembled from two 
synthetic fragments. The final peptide products were confirmed by LCMS. 
 
Vulnerability of the filovirus pre-hairpin intermediate 
 The key to success in applying our D-peptide inhibitor strategy to filoviruses is 
the presence of a vulnerable pre-hairpin intermediate during filovirus entry. Exogenous 
C-peptides derived from the transmembrane subunit of the envelope glycoprotein have 
been used to validate this vulnerable pre-hairpin intermediate in a variety of viruses (e.g., 
HIV, SARS, and many paramyxoviruses (31-33)). For filoviruses, an early report showed 
C-peptide inhibition activity at mM concentrations (34), and a more recent report 
described modest inhibitory activity (mid-µM) of a C-peptide with an endosomal 
localization tag (35). Our EboV N-trimer, eboIZN39IQ, provides an additional tool with 
which to explore the vulnerability of the pre-hairpin intermediate. In support of this 
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strategy, the peptide mimics of the HIV-1 N-trimer inhibit HIV entry at mid-nM 
concentrations by binding to the C-peptide region of the exposed intermediate. 
 Indeed, eboIZN39IQ inhibits entry in our pseudovirus system in which Ebola GP 
is expressed on the surface of an HIV particle, with an IC50 of 320 nM (averaged over 
four replicate experiments) (Fig. 5.8a). Importantly, the anti-EboV activity of our 
negative control, eboIZN39IQ(D3), is >30-fold diminished at an IC50 of 11 uM (averaged 
over three replicate experiments). The residual activity of eboIZN39IQ(D3) is unlikely to 
be due to specific pre-hairpin intermediate binding activity, since SPR analysis showed 
essentially no binding of eboIZN39IQ(D3) to the C-peptide (Fig. 5.4). However, it is 
difficult to determine the exact nature of the modest eboIZN39IQ(D3) activity, as it is not 
seen against VSV, and no morphological changes were observed via light microscopy in 
any of the wells throughout the assay.  eboIZN39IQ demonstrates modest activity against 
MarV, at an IC50 of 5.7 µM (averaged over duplicate experiments); however, it is only 
~2-fold better than the eboIZN39IQ(D3) anti-MarV activity. It is therefore difficult to 
determine if this indicates any specific activity due to cross reactivity with the MarV pre-
hairpin intermediate.  
The ability of eboIZN39IQ to inhibit the entry of wild-type EboV and MarV was 
also assessed using a filovirus immunofluorescence assay under BSL4 conditions (Fig. 
5.8b). Although eboIZN39IQ is significantly less potent in this assay, there is good 
inhibition of entry at the highest concentration tested, 10 µM, and no inhibition by our 
negative D3 control. Also, no activity was seen against authentic MarV. Taken together, 
these data validate the presence of a vulnerable pre-hairpin intermediate during the 
filovirus entry process. 
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 Unlike HIV-1, filoviruses enter cells via endocytosis and initiate membrane 
fusion late in the endosomal process. Therefore, filovirus entry inhibitors will have to 
enter into and be active in the endosomes. Although eboIZN39IQ does not possess a 
specific tag to localize it to endosomes, it is highly charged on its surface and may 
naturally interact with the cell membrane, allowing it to access the endosome more 
efficiently than C-peptides. Interestingly, the inhibitory activity we observe in both the 
pseudovirus and authenic EboV systems is dependent on the presence of DEAE-dextran. 
This cationic polymer may reduce electrostatic repulsion between eboIZN39IQ and the 
negatively charged cell membrane surface. As a highly structured peptide, it would also 
likely survive against proteolysis longer than unstructured C-peptides.  
 
Endosomal targeting 
 In order to achieve high potency, filovirus inhibitors will likely need to be 
targeted to the endosome. A variety of cationic tags have been described to traffic to or 
through the endosomes, such as HIV-1 Tat and poly-arginine sequences (as reviewed 
(36)), and Tat was required to confer inhibitory activity on an EboV C-peptide (35). 
However, we have tried a variety of these cationic tags, including one optimized for 
endosomal localization (37), on both EboV C-peptides and N-trimer mimics and none of 
them have convincingly improved inhibitory activity in a specific way (unpublished 
results).  Also, each of them contributed to cellular toxicity at concentrations slightly 
higher than observed inhibitor IC50s, visualized as morphological differences under the 
light microscope and/or slowed growth.  
 As an alternate strategy, we have fused cholesterol to our N-trimer mimic, and it 
appears to increase inhibitor potency in a specific fashion (preliminary data not shown). 
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Indeed, cholesterol conjugation increased the potency of our HIV-1-specific PIE12-trimer 
by two orders of magnitude by targeting it to cellular membranes (14). Further work 
needs to be done to confirm these preliminary data and to determine if this strategy will 
be useful for future inhibitors, especially in light of a recent paper that describes non-
specific inhibitory activity for a cholesterol-conjugated filovirus C-peptide (38). 
In the future, we will likely focus on targeting inhibitors to endosomes in a more 
specific manner. For example, transferrin receptor (TfR) transports iron into cells via an 
endosomal pathway. TfR is ubiquitously expressed, and is frequently used as an 
endosomal marker. In addition, many cancer therapies that use the TfR for targeted 
delivery are in development (as TfR is overexpressed in many cancer cells) (39). 
Specifically, a 7-residue peptide was identified via phage display to bind to TfR and has 
been used to target cancer therapies in preclinical studies (39-41). Fusing this peptide to a 
D-peptide that targets the filovirus pre-hairpin intermediate is one potential strategy for 
targeting inhibitors to the endosome. 
 
Conclusion 
 We have developed an ideal filovirus N-trimer target to be used in mirror-image 
phage display, eboIZN21. It is a stable trimeric coiled coil with low background phage 
binding, and easily synthesized in D. With eboIZN21 and a good positive control phage 
clone (eboC24-phage), we are poised for phage display selections.  
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Materials and Methods 
Reagents 
Plasmids and cells were obtained from the indicated sources: pKA8 vector (gift 
from C. Hill), pEBB-HXB2 (gift from B. Chen), SV-ZeboGPΔmuc and SVMarVGP (gift 
from M. Farzan) (42), BLR(DE3)pLysS E. coli (Novagen), BL21-Gold(DE3)pLysS E. 
coli and XL-1 Blue E. coli (Stratagene). pNL4–3.Luc.R-E- (N. Landau) (43, 44) and 
HOS-CD4-fusin (N.Landau) (45, 46) were obtained from the NIH AIDS Research and 
Reference Program. The mammalian cells were propagated in standard tissue culture 
medium, Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal 
calf serum (Invitrogen).  
 
Recombinant peptide production and purification 
 eboIZN39IQ and eboIZN39IQ(D3) were produced via PCR gene synthesis. The 
IZm and IQ fragments were PCR amplified from Kay lab plasmids encoding HIV-1 N-
trimer mimics. An NdeI site was included in the 5’ PCR primer for IZm, and a BamHI site 
was included in the 3’ PCR primer for IQ. The EboV N39 sequence was synthesized in 
two overlapping oligos and companion primers. All internal primers contained 
complementary sequences so the three separate components, IZm, N39, and IQ could be 
annealed and amplified together. The resulting DNA fragment was cloned into the 
NdeI/BamHI cloning sites of pKA8 and expressed in BLR(DE3)pLysS cells using an 
autoinduction protocol. Specifically, cultures were inoculated from a single colony and 
grown overnight at 37 °C in autoinduction media (47). The resultant peptide has an N-
terminal His tag (His8) followed by a TEV cleavage site (ENLYFQG). A single tyrosine 
was placed at the end of the sequence to facilitate concentration determination via 
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absorbance at 280 nm. The peptides were resuspended from inclusion bodies using a 
Ni++ Binding Buffer (20 nM Sodium Phosphate pH 8.0, 300 mM NaCl, 10 mM 
imidazole) + 6 M GuHCl, and purified via gravity flow Ni++ affinity chromatography 
(HIS-Select Nickel Affinity Gel, Sigma Aldrich). The purified peptide was dialyzed into 
5% acetic acid and further purified by reverse phase HPLC on a C18 column (Vydac) and 
lyophilized. Peptide powder was resuspended in water and then diluted to 0.2 mg/mL in 
50 mM Sodium Phosphate pH 6.5, 0.5 mM EDTA, 1 mM DTT and digested with TEVse 
(gift of C. Hill) overnight at 30 °C. The digested peptide was dialyzed into 5% acetic acid 
and then HPLC purified and lyophilized. The final peptide sequences are: 
GHMDIKKEIEAIKKEQEAIKKKIEAIEKELRQLANETTQ(A/D)LQLFLR(A/D)TTEL
RTFSILNRK(A/D)IDFLLQRMKQIEDKIEEIESKQKKIENEIARIKKLIGERY, with 
IZm and IQ shown in bold, the EboV N-trimer in italics, and the three alanine positions 
that are changed to aspartate in the D3 mutant in parentheses.  
 Biotinylated eboIZN39IQ and eboIZN39IQ(D3) for SPR analysis and phage 
display were expressed from plasmids that are slightly modified to those described above. 
Using PCR, a CGG sequence was added N-terminal to IZ (GHMCGGDIKK...). 
Expression and purification was as described above with additional reduction steps 
included to keep the cysteine reduced during purification. The purified protein was 
biotinylated with EZ-link Maleimide-PEG2-biotin (Thermo Scientific). The purified 
lyophilized powder was resuspended at 1 mM in freshly prepared reaction buffer (6 M 
GuHCl, 150 mM NaCl, 100 mM Na2HPO4, 5 mM TCEP) and the biotinylation reagent 
was added at 5 mM and allowed to react for 4 hr at RT. The biotinylated peptides were 
! 66 
purified by reverse phase HPLC on a C18 column (Waters) and lyophilized. The mass of 
the peptide was confirmed by LCMS (AB Sciex API 3000 LC/MS/MS system).  
 
Peptide synthesis 
 eboIZN21, eboIZN21(D2), eboC37, and eboC24 were chemically synthesized 
using solid-phase peptide synthesis (SPPS) with Fmoc-amino acids (CBL Biopharma) on 
the Prelude peptide synthesizer (PTI). They were synthesized on TentaGel R RAM resin 
(Rapp Polymere) to yield C-terminal amide-capped peptides. Standard synthesis scales 
were 25 - 32 µmol per peptide. Standard amino acid coupling was as follows: 3x3 min 
deprotection with 20% piperidine in DMF followed by 25 min couplings with 72.2 mM 
amino acid (200 mM stocks in NMP), 71.5 mM HATU (200 mM stock in DMF), and 
166.7 mM NMM (600 mM stock in DMF). Biotinylation with N-Biotinyl-NH-(PEG)2-
COOH DIPEA (20 atoms) (Novabiochem) was coupled for 2 hrs with identical reagent 
composition to a standard coupling. N-terminal capping was accomplished in 30 min 
with 2 mL acetic anhydride and 2 mL 0.6 M NMM either on- or off-line. Peptide 
cleavage from resin was accomplished off-line with 92.5% TFA, 2.5% EDT, 2.5% TIS, 
2.5% H2O when the peptide contained Met or Cys residue(s) or with 95% TFA, 2.5% 
TIS, 2.5% H2O in the absence of any Met/Cys residues followed by precipitation/washing 
with diethylether.  All peptides were purified by reverse-phase HPLC on a Waters BEH 
X-Bridge C18 column (10 μm, 300 Å, 19 x 250 mm) with a water/ACN gradient in 0.1% 
TFA. All peptides were lyophilized and their molecular weight verified by LCMS (AB 
Sciex API 3000 LC/MS/MS system).  
D-eboIZN39IQ was assembled from three synthetic peptide fragments via native 
chemical ligation/metal-free desulfurization. Peptides were synthesized via Fmoc-SPPS 
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on a PTI PS3 peptide synthesizer at 100 umol scale. The C-terminal peptide was 
synthesized on Rink Amide AM resin LL (Novabiochem) and the other two fragments 
were synthesized on Dawson Dbz AM resin (Novabiochem). The C-terminal fragment 
contained an N-terminal Fmoc-Cysteine-OH residue in the place of a native alanine for 
native chemical ligation (CIDFLLQRMKQIEDKIEEIESKQKKIENEIARIKKLIGERY). 
For the same reason, the middle fragment contained an N-terminal Boc-L-thiazolidine-4-
carboxylic acid (Boc-THZ-OH, Bachem) as its N-terminal residue in place of the native 
alanine at that position ((THZ)-NETTQALQLFLRATTELRTFSILNRK). The N-
terminus of the N-terminal peptide (GHMDIKKEIEAIKKEQEAIKKKIEAIEKELRQL) 
was biotinylated with N-Biotinyl-NH-(PEG)2-COOH DIPEA (Novabiochem). For 
peptides synthesized on Dawson Dbz AM resin, the C-terminal linker was converted to 
the resin bound benzimidazolinone (Nbz) according to manufacturer recommendations. 
Cleavage of all peptides was performed according to standard procedures. Peptides were 
purified by reverse-phase HPLC on a Waters BEH X-Bridge C18 column (10 μm, 300 Å, 
19 x 250 mm) with a water/acetonitrile gradient in 0.1% TFA. Ligations were performed 
according to (48). Following the ligation between the C-terminal and middle fragments, 
the N-terminal THZ residue was converted to cysteine by dissolving the purified ligation 
product in 6 M GuHCl, 200 mM sodium phosphate, 200 mM methoxyamine HCl, pH 4. 
After THZ to Cys conversion was achieved, the buffer was brought to 200 mM MPAA 
and 20 mM TCEP, the pH was adjusted to 7, and the N-terminal peptide was added to the 
solution for the final ligation. Following purification of the ligation product by reverse-
phase HPLC, the cysteine residues at the ligation junctions were converted to the native 
alanine residues via a metal-free, radical-mediated desulfurization strategy essentially as 
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described in (30) except tBuSH was replaced with glutathione and desulfurizations were 
performed at 37ºC. eboIZN39IQ(D3) was synthesized in an analogous (though 
simplified) manner from two peptide fragments. 
   
Preparation of peptide samples for biophysical analysis 
For biophysical analyses, peptide stocks were prepared in water from lyophilized 
peptide at concentrations of 400 μM or greater for a minimum absorbance at 280 nm of 
0.1 in a 1 cm pathlength cuvette. Stocks were centrifuged at 18,000 xg for 10 min to 
remove aggregates. Absorbance at 280 nm (assuming ε280 of 1408 M-1cm-1 for tyrosine) 
was used to determine stock concentrations (49). For eboIZN39IQ and eboIZN39IQ(D3), 
both recombinant and synthetic, UV absorbance consistently overestimated the 
concentration of the stocks (as evidenced by an unusually high 260/280 ratio as well as 
CD traces whose shape depicted ideal coiled coils but whose signal had a lower than 
expected absolute value). Therefore, the concentrations of these stocks were determined 
via quantitative amino acid analysis (D. Winge). The peptides were then diluted to the 
desired concentration in 50 mM Sodium Phosphate pH 5.8, 150 mM NaCl.  For 
eboIZN21 and eboIZN21(D2), all experiments described in this paper were performed 
with biotinylated peptide. For eboIZN39IQ and eboIZN39IQ(D3), CD, AUC, and viral 
infectivity were performed with nonbiotinylated material, whereas SPR and phage 
display used biotinylated material. 
 
Circular dichrosim 
Circular dichrosim (CD) data were obtained using an AVIV Model 410 
spectrophotometer (AVIV, Lakewood, NJ). Samples were analyzed in a 1 mm pathlength 
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quartz cuvette at 25, 37, and 50 °C. Prior to CD analysis, prepared samples (in 50 mM 
Sodium Phosphate pH 5.8, 150 mM NaCl) were centrifuged at 18,000 Xg for 10 min to 
remove aggregates. CD data were scanned in triplicate and buffer subtracted. Final CD 
data were presented according to mean residue ellipticity equation, [θ] = 100*θ/[(n-
1)*(ℓ)*(c)], where θ is observed ellipticity, n-1 is number of peptide bonds, ℓ is the 
pathlength in cm, and c is the peptide concentration in mM. Due to aggregation observed 
with eboIZN39IQ and eboIZN39IQ(D3) upon initial dilution in CD buffer, their final 
concentrations were corrected from the original amino acid analysis values based on the 
ratio of ellipticity at 222 nm post- and precentrifugation (θ222-post-spun/θ222-pre-spun). 
 
Analytical ultracentrifugation sedimentation equilibrium 
 Sedimentation equilibrium analysis was performed on each peptide at three 
concentrations each (a starting concentration and two 2-fold dilutions, with typical 
starting concentrations between 10-30 µM). Dilutions were prepared in matching buffer 
(50 mM Sodium phosphate, 150 mM NaCl, pH 5.8), and the same buffer was used for 
blanks.  Each sample was spun until equilibrium, typically ~24 hrs, at a minimum of two 
speeds, but typically three speeds (18,000, 21,000, and 24,000 RPM). Each data set was 
globally fit to a single ideal species with a nonlinear least squares algorithm as 
implemented in HETEROANALYSIS (50).  Buffer densities and protein partial specific 
volumes were calculated with SEDNTERP (version 1.09) (51). For the biotinylated 
peptides, partial specific volumes were adjusted based on reported values for PEG (52). 
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Surface plasmon resonance 
 SPR analysis was conducted on the Bio-Rad ProteOn instrument in PBS* running 
buffer (50 mM Sodium Phosphate, 150 mM NaCl, pH 5.8) + 0.1 mg/mL BSA and 0.01% 
Tween-20. Approximately 600 RUs of Biotin-eboIZN39IQ and Biotin-eboIZN39IQ(D3) 
targets (200 nM stocks ultracentrifuged for 30 min at 45,000 rpm) were loaded at 66 - 
200 nM onto the NLC neutravidin-coated chip. Using the one-shot kinetics method, a 2-
fold dilution series was performed in triplicate at RT starting at 60 nM for eboC37 and a 
3-fold dilution series in triplicate at RT starting at 5 µM for eboC24. 10 min dissociation 
time for eboC37 and 5 min dissociate time for eboC24 was used to ensure the response 
fully recovered to baseline prior to the next injection. Data were fitted to the Langmuir 
binding model using ProteOn Manager software (Bio-Rad).  
 
Clonal phage production 
 Forward and reverse sandwich oligos encoding the C-peptide clones were 
designed based on the primary sequence of each clone.  The oligo sandwich was annealed 
with 5 µg of each primer in 50 µL total volume in ddH2O by heating to 95°C and slow 
cooling and then extended with Klenow Fragment (NEB). The inserts and M13KE 
cloning vector backbone (NEB) were digested with Acc65I and EagI-HF. The insert 
DNA was EtOH precipitated and then gel purified from a 6% TBE acrylamide gel using a 
Bio-Rad Freeze n Squeeze device. The inserts and backbone were ligated and 
transformed into SS320 electrocompetent cells. After brief recovery, the transformed 
cells were added to fresh XL-1 Blue cells and plated on LB/IPTG/X-gal plates. The DNA 
from specific phage plaques was PCR amplified and Sanger sequenced (Eton 
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Biosciences), and those containing the correct DNA were subsequently amplified from a 
single plaque.  
 
Phage amplification 
 A single plaque was added to XL-1 Blue cells (OD600 0.5 – 1), diluted to 40 mL of 
OD600 0.05 in LB + 25 µg/mL tetracycline, and shaken at 220 RPM at 37°C for 4.5 – 5 
hrs. Cells were pelleted by centrifugation, and the phage supernatant was sterile filtered. 
Phage were precipitated with PEG-NaCl (20% w/v polyethylene glycol-8000 (Fisher 
Scientific), 2.5 M NaCl) overnight at 4°C. Precipitated phage were then pelleted via 
centrifugation and resuspended in TBS (50 mM Tris-HCl, 150 mM NaCl, pH 7.4). They 
were PEG-precipitated again (~1 hr on ice), centrifuged, and resuspended in 200 µL TBS. 
Aliquots were flash frozen and stored at -20°C with a working stock left at 4°C if 
imminent experiments were planned. 
 
Clonal phage ELISA 
 For each phage ELISA reaction, 30 µL Streptavidin-coated magnetic beads 
(Invitrogen, 10 mg/mL Dynabeads MyOne, Streptavidin T1) at 10 mg/mL were 
magnetically pelleted and washed with 3.33x bead volume TBS. The beads were then 
blocked in 3.33x bead volume 100% SB (ThermoScientific, SuperBlock Blocking Buffer 
in TBS, pH 7.4) for 10 min at RT and rinsed with equal volume of 100% SB* (SB 
adjusted to pH 5.8 with HCl). Solution-phase beads were then resuspended in 3.33x bead 
volume of 100% SB* and stored at 4°C for up to 24 hrs. Solid-phase beads were 
resuspended in 3.33x bead volume PBS* (50 mM Sodium Phosphate, 150 mM NaCl, pH 
5.8) + 10% SB*. To load target onto solid-phase beads, 1x bead volume of an appropriate 
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target concentration (e.g., 10 µM target for 10 µM beads) was added and incubated for 10 
min followed by adding 3.33x bead volume 5 mM D-Biotin (in PBS* + 10% SB*) and 
incubating for an additional 5 min. For blank (no target) beads, 3.33x bead volume of 5 
mM D-Biotin was added and incubated for 5 min. All beads were then magnetically 
pelleted, washed in PBS* and resuspended in 1x bead volume PBS* + 10% SB*. 
 Solid-phase binding reactions were incubated in 96-well format (Costar, sterile 
polystyrene, V-bottom, nontreated) with shaking for at least 2 hrs at RT either as 30 or 
100 µL reactions in 1x PBST* (50 mM Sodium phosphate, 150 mM NaCl, pH 5.8, 0.01% 
Tween-20) + 10% SB* and 1010 phage clone added. All washes and elution were done on 
the KingFisher Duo magnetic particle processor (Thermo Scientific). The binding 
reaction was mixed on the KingFisher for 1 min at medium speed and the beads collected 
by 5 sec dips of the magnet through the sample, repeated 5 times (5 x 5 sec). All washes 
were done with PBST* (wash 1: 700 µL; wash 2: 800 µL; wash 3: 900 µL; washes 4-7: 
1000 µL), mixed at slow speed for 1.5 min, and beads collected 3 x 3 sec. Bound phage 
were eluted with 50 µL EB (0.2 M glycine, pH 2.2) for 10 min, beads collected 5 x 5 sec, 
and neutralized with 7.5 µL NB (1 M Tris, pH 9.1). Dilutions of eluted phage were used 
to infect XL-1 Blue cells and then plated in top agar (40% LB agar/60% LB) on 
LB/IPTG/X-gal plates (LB agar, 25 µg/mL tetracycline, 1 mM IPTG, 0.1 mg/mL Xgal). 
Blue plaques were then counted to determine phage titers.  
 Solution-phase binding reactions were performed similarly to solid-phase 30 µL 
reactions. Instead of adding target-loaded beads to the binding reaction, an appropriate 
amount of soluble target (10x target added to 10% of total reaction volume) was added to 
the reaction just before phage were added. Additionally, on the Kingfisher Duo, target 
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and bound phage were pulled down in a rapid 1 min magnetic pelleting step (1 min slow 
mixing, 5 x 5 sec bead collect). All washes were done with PBST* except wash 1 which 
contained 5 mM D-Biotin to block unoccupied streptavidin sites (wash 1: 150 µL; wash 
2: 700 µL; wash 3: 800 µL; wash 4: 900 µL; wash 5: 1000 µL), mixed at slow speed for 
25 sec, and beads collected 3 x 3 sec.  
 
Pseudovirus infectivity assays 
 Single-cycle pseudovirions were produced with a pNL4-3 HIV-1 genome with 
firefly luciferase inserted into the nef gene and frameshift mutations in both Env and Vpr 
and expressing filovirus GP on their surface (or VSV for a specificity control). These 
pseudovirions were produced by co-transfecting 293T human embryonic kidney cells 
with the described HIV-1 genome (pNL4-3.Luc.R-E-) and a plasmid encoding the 
desired virus glycoprotein (SV-ZeboGPΔmuc for EboV Zaire GP lacking the mucin 
domain, SV-MarVGP for MarV Musoke GP, and pMDG VSV-G for VSV) in the 
presence of PEI transfection reagent. Pseudovirus-containing supernatant was collected 
and filtered 38-43 hrs posttransfection. For EboV and MarV, pseudovirions were 
concentrated by centrifuging through a 20% sucrose/TNE (10 mM Tris pH 7.6, 100 mM 
NaCl, 1 mM EDTA)  cushion (26,000 RPM, 2 hrs), and then the pellet was resuspended 
in TNE, aliquoted, and stored at -80 °C.  
 To measure inhibition of infectivity, 90 uL of each inhibitor dilution and 8.9 
ug/mL DEAE-dextran were added to HOS-CD4-fusion cells in a 96-well format. The 
plates were then transferred to BSL3, and 10 uL of pseudovirus diluted in media was 
added to each well 30-60 min after the inhibitor addition (final DEAE-dextran 
concentration of 8 ug/mL). 24 hrs later, all wells were inspected under light microscope 
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to check for gross morphological changes. Virus and inhibitor were then removed via 
aspiration, and fresh media was replenished. 20-24 hrs later, the cells were lysed, and the 
luciferase activity was measured (Bright-Glo luciferase assay system, Promega). To 
determine IC50 values, the data from each inhibitor concentration series were normalized 
to the noninhibitor control signal and then was fit to a Langmuir equation: y = 
1/(1+[inhibitor]/IC50) (Kaleidagraph, Synergy Software). The curve fit was weighted by 
the normalized standard error of each concentration point (with a minimum error allowed 
of 1%).  
 
Filovirus immunofluorescence assays 
 Vero cells were seeded in 96 well black plates. Peptides and vehicle control were 
diluted to 1.1X final concentration in culture media and incubated on the plate for 1 hr at 
37 °C.  In the BSL4, 10 uL of virus diluted in media and DEAE-dextran was added to 
each well (final DEAE-dextran concentration of 8 μg/mL). For EboV Zaire, infections 
were performed at 1, 0.1, and 0.01 MOI of virus. For MarV, infections were performed at 
1.0 MOI only. After 1 hr at 37 °C, the virus and peptides were removed, the wells were 
washed with PBS, and media with peptide was used to replenish the wells. At 24 hrs 
postinfection, each well wash visualized via light microscope to look for any gross 
morphological abnormalities. At 48 hrs postinfection, the wells were washed with PBS 
and then the cells fixed with 10% formalin. After blocking, the fixed cells were incubated 
with GP-specific mAb (9g4 for MarV, KZ52 for EboV) followed by incubation with 
FITC-labeled secondary antibody (goat anti-mouse or anti-human, respectively). Nuclei 
were stained with Hoechst solution. Cells were imaged using an Operetta high content 
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device and images were analyzed using Harmony software to determine percent of 
infected cells in a given well. Data were plotted normalized to the vehicle control.  
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Figure 5.1. Model for membrane fusion mediated by enveloped viral surface 
glycoproteins. The HIV-1 and filovirus entry events are predicted to be highly similar. 
First, the surface glycoprotein (Env for HIV-1, GP for filoviruses) facilitates viral 
attachment to the cell and, for filoviruses, the virus is endocytosed and then cleaved by 
endosomal proteases. Engagement of the virus receptors (CD4 and a chemokine receptor 
for HIV-1, NPC1 for filoviruses) leads to a conformational change in Env/GP, and 
insertion of the fusion peptide/loop into the host cell membrane. At this state, the virus is 
in a transient state that bridges both membranes, termed the “pre-hairpin intermediate.” It 
is now vulnerable to inhibitors that bind the pre-hairpin intermediate and inhibit entry. In 
the absence of an inhibitor, the Env/GP structure slowly resolves into the highly stable 
trimer-of-hairpins structure, juxtaposing the two membranes and leading to membrane 
fusion. The inset shows the high resolution structure of the EboV trimer-of-hairpins (25). 
In the HIV model system, it has been shown that inhibitors that bind to either the N-
trimer or C-peptide region are capable of inhibiting entry. 
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Figure 5.2. Biophysical analyses of EboV N-trimer mimics. A) CD spectra of 11.4 µM 
eboIZN39IQ and 11.1 µM eboIZN39IQ(D3) at 25 °C. Both spectra indicate a highly 
helical conformation. B) CD spectra of 18.0 µM eboIZN21 and 25.3 µM eboIZN21(D2) 
at 25 °C, also indicative of a completely helical conformation. C) Analytical 
ultracentrifugation (AUC) sedimentation equilibrium analysis of eboIZN39IQ(D3), 
shown as representative AUC data. 8, 4, and 2 µM peptide was centrifuged at 18,000, 
21,000, and 24,000 RPM at 25 °C on a Beckman XLA. Data were globally fit to a single 
ideal species, and an observed molecular weight of 37,278 Da was determined for an 
Mobs/Mcalc of 3.07. The data (open symbols) and fit (solid lines) are shown for the highest 
speed. 
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Zaire       LRQLANETTQALQLFLRATTE 
Taï Forest  LRQLANETTQALQLFLRATTE 
Bundibugyo  LRQLANETTQALQLFLRATTE 
Sudan       LRQLANETTQALQLFLRATTE 
Reston*     LRQLANETTQALQLFLRATTE 
Marburg     LRRLANQTAKSLELLLRVTTE 
Ravn        LRRLANQTAKSLELLLRVTTE 
Lloviu*     LRELANTTTKALQLFLRATTE 
 
Figure 5.3. Alignment of N21 from GP of the 5 known EboV species, Marburg, 
Ravn, and Lloviu hemorrhagic fever filoviruses. Conserved residues (score of 0 or 
higher in BLOSUM62 matrix (53)) highlighted in gray. All changes are conserved except 
for the E/Q to T substitution in Lloviu. *Reston and likely Lloviu are not pathogenic to 
humans. 
 
 
 
 
Figure 5.4. Affinity measurement of the EboV C-peptide for the N-trimer mimic. 
Top: Sensogram of eboC37 flowed over eboIZN39IQ(D3) in a 2-fold dilution series 
starting at 60 nM. Little to no binding is observed.  Bottom: The same eboC37 dilutions 
flowed over an eboIZN39IQ surface. The fit indicates a KD of 7.5 nM.  
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Figure 5.5. Solution-phase clonal phage ELISA of EboV C-peptides binding to 
eboIZN39IQ. eboC37 (orange) and eboC24 (green) phage binding to blank beads (NT), 
eboIZN39IQ, and eboIZN39IQ(D3) is shown. Control phage, M13KE, binding was also 
assessed (gray). Where present, error bars represent standard error across multiple 
experiments for the C37 and M13KE data (n=3) and standard deviation for the C24 data 
(n=2).  
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Figure 5.6. Solid-phase clonal phage ELISA validating the eboIZN21 target in the 
context of phage display.  eboC24 (green) phage binding to blank beads (NT), 
eboIZN21, and eboIZN21(D2) is shown. Control phage, M13KE, binding to blank beads 
(NT), and eboIZN21 was also determined. Where indicated, error bars represent the 
standard error of data from four experiments. 
! 81 
 
 
!
!
Figure 5.7. Comparing the two EboV N-trimer mimics as phage display targets. 
Phage background binding is greater to eboIZN39IQ than to eboIZN21. Phage ELISA 
showing M13KE control phage binding to eboIZN39IQ (left) and eboIZN21 (right) under 
both solid-phase and solution-phase conditions. High stringency solution-phase binding 
shows an affinity difference for eboC24. Experiments were repeated and representative 
data shown. 
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Figure 5.8. Inhibition of filovirus entry by eboIZN39IQ. A) A representative 
pseudovirion assay looking at the inhibitory activity of eboIZN39IQ and the negative 
control, eboIZN39IQ(D3) against EboV, MarV, and VSV retroviral pseudotypes. Each 
point represents the average of quadruplicate measurements normalized to uninhibited 
control. Error bars represent normalized standard errors. For this particular assay, 
eboIZN39IQ IC50s are 260 nM against EboV and 5.4 µM against MarV. B) Data for the 
authentic filovirus immunofluorescence inhibition assay. Each point represents the 
average of quadruplicate measurements normalized to vehicle control. 
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Table 5.1. CD analysis of eboV N-trimer mimics 
Peptide ɵ222 nm (deg 
cm2 dmol-1) 
25 °C 
ɵ222 nm (deg 
cm2 dmol-1) 
37 °C 
ɵ222 nm (deg 
cm2 dmol-1) 
50 °C 
Mobs/Mcalc 
4 °C 
eboIZN39IQ -29,351 -27,910 -27,083 3.19 
eboIZN39IQ(D3) -30,369 -29,348 -28,353 3.22 
eboIZN21 -25,520 -23,989 -22,868 3.45 
eboIZN21(D2) -24,849 -22,762 -21,847 3.16 
 
CD scans were performed on the same samples at 11.4 uM eboIZN39IQ, 11.1 uM 
eboIZN39IQ(D3), 18.0 uM eboIZN21, and 25.3 uM eboIZN21(D2) in 50 mM Sodium 
phosphate, pH 5.8, 150 mM NaCl at 25 °C, 37 °C, and 50 °C. The peptides were allowed 
to equilibrate at each temperature for 10 min, after which no change in signal was seen 
over time. Sedimentation equilibrium analysis was performed on each peptide at three 
concentrations each (a starting concentration and two 2-fold dilutions, with typical 
starting concentrations between 10-30 μM) and a minimum of two speeds, but typically 
three speeds (18,000, 21,000, and 24,000 RPM). Each data set was globally fit to a single 
ideal species with a nonlinear least squares algorithm. Each sedimentation equilibrium 
analysis was performed 1 to 3 times and averaged for the above table.  
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Introduction 
 
All known living organisms utilize proteins composed of L-amino acids.  Mirror-
image D-peptides/proteins are promising therapeutic agents due to their resistance to 
degradation by natural proteases (1) and are also of great interest to synthetic biologists 
(mirror-image life) (2).  Mirror-image proteins are not found in nature and are only 
accessible through chemical synthesis.  Recent advances in chemical protein synthesis are 
making production of larger proteins more feasible, but a major anticipated challenge is 
the folding of synthetic proteins into their active conformations.  In vivo, molecular 
chaperones, such as the extensively studied bacterial chaperone GroEL/ES, mediate 
folding and prevent aggregation of a large group of cellular proteins (3, 4).  GroEL/ES is 
thought to interact with these diverse substrates via nonspecific hydrophobic interactions, 
but it is unknown whether it can recognize and fold mirror-image proteins. Here we 
examine the chiral specificity of GroEL/ES by studying the ability of this natural 
chaperone to fold a synthetic D-protein. This study required the total chemical synthesis 
of a 312-residue GroEL/ES-dependent protein, dapA, in both L- and D-chiralities, the 
longest synthetic proteins yet reported.  We used these synthetic proteins to demonstrate 
that E. coli GroEL/ES folds both L- and D- forms of dapA with similar efficiency. This 
work extends the limits of chemical protein synthesis, reveals a previously unknown 
ambidextrous protein folding activity in GroEL/ES, and shows that natural chaperones 
can be used to fold D-proteins for drug development and mirror-image life applications. 
 The binding of substrates by GroEL is an intriguing instance of promiscuous 
molecular recognition.  GroEL has been shown to interact transiently with approximately 
250 cytosolic proteins in E. coli under normal growth conditions (5, 6).  A subset of these 
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proteins exhibit an absolute requirement for GroEL and its cochaperone GroES to avoid 
aggregation and fold into their native state (6, 7).  Interestingly, sequence analysis of the 
known set of GroEL/ES obligate substrates reveals no obvious consensus binding 
sequence (5), though structurally they are enriched in aggregation-prone folds (7).  
Furthermore, ~50% of soluble proteins from E. coli extracts will interact with GroEL 
when they are in a partially or fully unfolded conformation, but not in their native states 
(8).   
 Protein substrates trapped in non-native states have been shown to present 
hydrophobic surfaces that are otherwise buried in the core of the correctly folded protein.  
The thermodynamics of binding of these non-native states to GroEL imply a hydrophobic 
interaction (9), which is further supported by the hydrophobic character of GroEL apical 
domain residues implicated in substrate binding (10).  Previous studies on the basis of 
substrate interaction with GroEL using short model peptides have concluded that the 
most important determinant of binding is the presentation of a cluster of hydrophobic 
residues by the substrate (11-13).  The only evidence addressing the chiral specificity of 
GroEL/ES comes from a study that qualitatively demonstrated binding of a short D-
peptide to GroEL (12).   However, this NMR study required peptide concentrations that 
greatly exceed physiologic levels and did not localize the interaction to the substrate-
binding region of GroEL.  Until now, it has not been possible to directly test the stereo-
specificity of the GroEL/ES folding reaction because of synthetic limitations in 
producing large D-proteins, leaving open the question of whether GroEL/ES substrate 
binding or folding activity is stereo-specific.    
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 Due to our interest in mirror-image proteins as targets for drug discovery (14, 15) 
and mirror-image synthetic biology (e.g., the “D. coli” project, see below), we were 
intrigued by the possibility that GroEL/ES could assist in the folding of D-proteins.  
Thus, we decided to rigorously assess chiral specificity in the chaperone activity of 
GroEL/ES by synthesizing a D-version of a substrate protein and evaluating its folding 
by GroEL/ES.  Furthermore, because most GroEL/ES substrate proteins are large (>250 
residues), we reasoned that this project would provide an excellent opportunity to 
overcome the current limits of chemical protein synthesis.   
 
Results and Discussion 
 We began by searching for a model protein that (a) requires GroEL/ES for folding 
under physiologic conditions and (b) has a robust activity assay that does not depend on 
complex chiral reagents (e.g., cofactors or other enzymes that would also have to be 
synthesized in mirror-image).  The E. coli dapA protein (4-hydroxy-
tetrahydrodipicolinate synthase, E.C. 4.3.3.7) meets these criteria (Fig. 6.1a,b).  DapA is 
a 31 kDa protein that forms a homotetramer (16) and catalyzes the condensation of L-
aspartate-β-semialdehyde and pyruvate to (4S)-4-hydroxy-2,3,4,5-tetrahydro-(2S)-
dipicolinic acid (17-19), a key step in the biosynthesis of lysine and diaminopimelic acid 
(DAP), a cell-wall precursor. 
 DapA is highly enriched in GroEL/ES complexes under normal growth conditions 
(6) and is insoluble in GroEL-depleted cells (7).  In E. coli GroEL depletion strains, cell 
death occurs via lysis due to a loss in cell wall integrity resulting from a lack of dapA 
activity, further demonstrating the dependence of dapA on GroEL/ES to adopt its native 
structure (20).  Indeed, in vitro, dapA is absolutely dependent on GroEL/ES for proper 
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folding upon dilution from denaturant into physiologic buffer at 37ºC (6) (Fig. 6.2a).   
 Because D-proteins can only be accessed through chemical synthesis at present, a 
synthetic route to dapA was devised.  Synthetic peptides are routinely made using solid-
phase peptide synthesis (SPPS), but a project of this magnitude (312 residues) is well 
outside the capability of current SPPS technology (generally ~50 residues).  In order to 
access larger synthetic assemblies, chemoselective ligation techniques are used to 
assemble peptide fragments into larger constructs (21).  We employed a recently 
developed method to join peptide fragments via native peptide bonds formed between a 
peptide with a C-terminal hydrazide and a peptide with an N-terminal Cys (22).  We 
selected this chemistry because of the convenient route to peptide hydrazides via Fmoc 
SPPS, the robustness of the ligation reaction, and the flexibility to carry out protein 
assembly in either N- to C- or C- to N-terminal directions (allowing for convergent as 
opposed to traditional linear C- to N-assembly).  
 Our retrosynthetic analysis began by locating all Cys residues (potential ligation 
junctions) in dapA (Fig. 6.1b), all of which are located at acceptable ligation junctions 
(see (22) for a discussion of unacceptable junctions).  This information allowed us to 
break the protein into six fragments.  We were initially concerned that the length of the 
second fragment (80 residues) and the fourth fragment (77 residues) would make 
synthesis/isolation of the correct product difficult.   
 To expand the range of potential ligation junctions, we utilized a free-radical-
based desulfurization reaction that enables selective conversion of unprotected Cys into 
Ala (23).  This technique allows one to mutate a native Ala residue to Cys during peptide 
synthesis (for use in ligation), and then convert the Cys back to the native Ala following 
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assembly.  Using this methodology, we introduced two additional junction sites at A57 
and A191, resulting in eight fragments overall, ranging in size from 27 to 50 residues.  
We refer to these peptides as dapA 1 through 8 (Fig. 6.3).  Using highly optimized SPPS 
reaction conditions and RP-HPLC column selection, we synthesized and purified all eight 
peptides.  
Our initial strategy for the assembly of these eight fragments required 12 steps 
and their associated purifications (seven ligations, two desulfurizations, three Acm 
removals; Fig. 6.4).  Acm is an orthogonal Cys protecting group that prevents 
cyclization/polymerization  of peptides containing both an activated C-terminal hydrazide 
and an N-terminal Cys, and can also be used to prevent Cys desulfurization.  We found 
that while we were able to assemble the C-terminal portion (dapA 5-8), we were unable 
to assemble the N-terminal portion (dapA 1-4) following this scheme.  A significant 
complication was the His thioester on dapA 2 (H56), which was highly susceptible to 
hydrolysis, leading to low reaction yields during the dapA 2 to 3 ligation step (Fig. 6.5). 
This difficulty, coupled with the large number of manipulations (and concomitant sample 
losses), resulted in a failure to assemble dapA 1-4 in usable yield. 
 In order to overcome these synthetic difficulties, we employed two strategies to 
reduce the complexity of our assembly scheme.  First, we observed that we could 
simplify the original assembly strategy if we eliminated the desulfurization step 
necessary to convert the Cys to native Ala at the dapA 2-3 junction.  Towards this end, 
we determined locations in our protein that would likely tolerate permanent mutation to 
Cys.  We began by performing BLAST analysis of the E. coli dapA to identify the most 
similar homologs, aligning the top 1000 hits (>69% conservation, >49% identity) to 
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determine positions where Cys residues naturally occur.  Fortuitously, 12% of the aligned 
sequences contained Cys at position 57, site of the dapA 2-3 junction (Fig. 6.6a).  Next, 
we analyzed the dapA crystal structure to determine the likelihood of the A57C mutation 
to disrupt protein structure/function.  The side-chain of residue 57 is surface exposed and 
is not in close proximity to the active site or any native Cys residues  (>12 Å to the 
nearest Cys) (Fig. 6.6b).  These results suggested that introduction of the A57C mutation 
would likely be well tolerated.  Indeed, mutagenesis of dapA (dapA A57C) confirmed 
this prediction, as the mutation affected neither recombinant protein activity (Fig. 6.2b) 
nor its dependence on GroEL/ES for folding under physiological conditions (Fig. 6.2a).   
 Our second approach to reducing the number of assembly steps was to synthesize 
longer initial peptide fragments via SPPS, which was greatly aided by the use of 
pseudoproline dipeptides (known to disrupt aggregation during SPPS) (24). With 
optimized conditions, we successfully synthesized and purified dapA 1-2, dapA 5-6, and 
dapA 7-8 as single peptides, but we were unable to synthesize and purify dapA 3-4 in 
sufficient yield and purity (Fig. 6.7).   
 By combining rational mutagenesis (to eliminate desulfurization/Acm removal 
and associated purifications) with longer starting peptide fragments (some of which were 
dependent on pseudoproline dipeptides for sufficient purity/yield), we assembled L-dapA 
A57C from five fragments using five assembly steps (Fig. 6.8).  However, due to the lack 
of commercially available D-pseudoproline dipeptides required for the D- syntheses of 
dapA 1-2 and dapA 5-6, we ultimately selected a final assembly strategy that 
incorporated both the A57C mutation and the dapA 7-8 unified fragment, which did not 
depend on pseduoprolines.  This final strategy yielded a seven-fragment assembly 
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scheme (Figs. 6.3 and 6.9), ultimately removing four steps (and associated purifications) 
from the initial scheme.   
Following this final simplified strategy, we successfully assembled the 312-
residue synthetic dapA A57C (hereafter referred to as “dapA”) in both L- and D- 
chiralities (Figs. 6.10, 6.11, and 6.12), the longest synthetic proteins (in both chiralities) 
reported to date.  The proteins were synthesized at milligram scale (1.66 mg of D-dapA, 
total yield of 1.14%), which is a >200-fold improvement over the longest previously 
reported nonrepetitive synthetic protein (the 286-residue F-ATPase γ subunit, of which 
~30 µg was synthesized, at <0.005% yield (25)).  The synthetic L- and D-proteins 
behaved identically to recombinant dapA on a C4 RP-HPLC column  (Fig. 6.10a) and 
possess the correct molecular weights (Fig. 6.10b, c) 
 Because our synthetic proteins are denatured during the assembly process, we 
developed a chemical folding protocol to fold dapA in the absence of GroEL/ES (Fig. 
6.13a), providing a means to evaluate enzymatic activity of our synthetic constructs. Our 
method employs 0.5 M L-arginine (a protein refolding additive (26)), was validated using 
recombinant dapA, and works equally well with D-arginine (Fig. 6.13b).  After arginine-
assisted folding of synthetic L- and D-dapA, we used size exclusion chromatography 
(SEC) to isolate highly active tetrameric protein, removing unfolded material (Fig. 6.14).  
Following SEC, both the L- and D-dapA synthetic constructs have the expected CD 
spectra (Fig. 6.15a; note D-dapA’s mirror-image spectrum was inverted to aid 
comparison with L-dapA) and proved to be enzymatically active (Fig. 6.15b), 
demonstrating that our synthetic material is correctly folded and functional. 
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 With folded and validated synthetic L- and D-dapA in hand, we were poised to 
perform the definitive experiment comparing the folding of our synthetic L- and D-dapA 
by GroEL/ES.  The proteins were denatured in 6 M GuHCl and diluted into GroEL/ES-
containing buffer to initiate refolding.  Both synthetic L- and D-dapA recovered 
significant activity after GroEL/ES-mediated refolding (Fig. 6.16).  Interestingly, the 
refolding of D-dapA was slightly less efficient than synthetic L-dapA, which may reflect 
a subtle difference(s) in the interaction of the GroEL apical domain with D-dapA.  
 Importantly, the results presented here demonstrate that GroEL/ES is able to fold 
a D-protein and therefore does not manifest strict stereo-specificity in folding its 
substrates.  This result provides strong support for a substrate binding mechanism via 
nonspecific hydrophobic interactions followed by sequestration in a passive Anfinsen 
cage (3).  Our study provides proof-of-concept for the use of natural (L-) GroEL/ES to 
fold D-proteins for mirror-image drug discovery and synthetic biology applications.  It is 
now possible to envision the use of a GroEL/ES-containing bioreactor for folding of 
mirror-image proteins (27). 
 We note that synthetic L- and D-dapA possess ~20% lower specific activity 
compared to recombinant despite having the correct molecular weight.  We speculate that 
this difference is due to subtle defects in a fraction of the material (e.g., epimerization 
(28, 29)).   Determining the nature of and polishing these defects will be crucial to 
expanding application of this work to even larger synthetic proteins. 
 In order to determine if the ability of GroEL/ES to fold D-proteins is universal, 
we are pursuing the total chemical synthesis of D-GroEL (548 residues) and D-GroES 
(97 residues), which will then be screened in refolding assays against a suite of well-
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characterized recombinant L-substrates.  The D-GroEL/ES project will also further 
advance synthesis methodologies for the assembly of large proteins, giving complete 
control over the proteome with atomic precision.   
 The ability to chemically synthesize proteins of interest not only serves to 
advance mirror-image drug discovery efforts by making larger targets available, but also 
provides alluring possibilities for mirror-image synthetic biology (2).  It also 
complements other efforts to synthesize large biomolecules (e.g., synthetic genomes 
(30)).  An intriguing prospect is the assembly of a mirror-image in vitro translation 
apparatus (D-ribosome) and eventually a mirror-image organism, an effort that we have 
dubbed the “D. coli” project (14).  Such an organism would not only provide a facile 
route to mirror-image biomolecules, but would also have the added benefit of a “chiral 
firewall” that would prevent DNA exchange (horizontal gene transfer) and infection by 
other organisms (e.g., phage). A mirror-image organism would likely be unable to 
survive outside the lab due to the lack of necessary mirror-image nutrients in nature (a 
hypothesis we are currently investigating by exposing E. coli to a simulated mirror-image 
world).  This organism could also permit the study of highly pathogenic agents in mirror-
image, which have the same physiochemical properties as their enantiomeric counterparts 
without the toxicity of the naturally occurring forms.  In the short term, synthetic mirror-
image proteins will facilitate structural/biochemical studies of highly toxic proteins and 
mirror-image drug development.   
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Full Methods 
 
Recombinant dapA proteins 
The coding region of dapA was PCR amplified from E. coli BL21 (DE3) 
(Novagen) genomic DNA and inserted into the pET14b vector (Novagen) between NdeI 
and BamHI restriction sites, yielding a construct with an N-terminal hexahistidine tag and 
thrombin cleavage site (pET14b_dapA).  pET14b_dapA_A57C (a construct with the 
A57C mutation) was generated by mutating dapA codon 57 from GCT to TGC using the 
Q5® Site-Directed Mutagenesis Kit (NEB) with pET14b_dapA as the template, and was 
confirmed by sequencing of the entire gene.  Proteins were expressed in BL21 (DE3) 
cells (Novagen).  Cultures were grown in autoinduction media (31) in shake flasks at 
37ºC to an OD600 of 0.7-1 and then allowed to grow for an additional 14-18 hrs at 19ºC.  
Cell pellets were suspended in buffer A (50 mM Tris pH 7.3, 300 mM NaCl, 5 mM 
imidazole, 5% glycerol) and disrupted by sonication.  Samples were clarified by 
centrifugation, and protein was isolated from the supernatant by applying to His-Select 
Ni-affinity resin (Sigma), thoroughly washing with buffer A, and eluting in buffer A 
containing 250 mM imidazole.  Purified fractions were pooled, dialyzed against buffer A 
without imidazole, spin concentrated to ~8 mg/mL, aliquoted, flash frozen, and stored at -
80ºC.  A portion of the material was further purified via reverse-phase HPLC and 
lyophilized for use in refolding studies.   
 
GroEL and GroES 
 
GroEL and GroES were expressed in E. coli DH5α from the pBRE-groESL+ 
plasmid (F. Keppel and C. Georgopoulos, unpublished), which contains the E. coli groE 
operon.  Cultures were grown at 37ºC in shake flasks to an OD600 of 0.6.  An equal 
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volume of 55ºC media was added and the cultures were shifted to 43ºC for 3 hrs to 
induce expression of groE.  Cell pellets were resuspended in buffer (50 mM Tris pH 8, 1 
mM EDTA, 1 mM DTT) containing 0.17 mg/mL PMSF and lysed by incubation with 
lysozyme, followed by sonication and centrifugation.  GroEL was purified as described in 
(32).  GroES was essentially purified as described in (28) with the following 
modifications.  A 5 mL HiTrap Q HP column (GE Healthcare) was used instead of a DE-
52 column.  Eluted fractions containing GroES were dialyzed at 4ºC into 25 mM Tris (pH 
8 at 4ºC), 0.5 mM EDTA, 1 mM DTT.  1 M NaOAc pH 4.6 was added to 75 mM and the 
sample was stirred on ice for 15 min, filtered through a 0.2 μm pore size membrane, and 
then purified on a 1 mL HiTrap SP XL column (GE Healthcare) with a NaCl gradient (0-
500 mM over 15 column volumes) in 50 mM NaOAc, 0.5 mM EDTA, 2mM DTT, pH 
4.6.  Fractions containing GroES as judged by SDS-PAGE and LC/MS analysis were 
pooled, dialyzed against 25 mM Tris pH 7.5 (pH 8 at 4ºC), 0.5 mM EDTA, 1 mM DTT, 
and concentrated in an Amicon Ultra-15 centrifugal concentrator.  Concentrations were 
determined by absorbance at 280 mm (GroES) or Bradford method (GroEL).  Glycerol 
was added to 10%, and aliquots were flash frozen and stored at -80ºC.   
 
Peptide synthesis 
 
Peptides were synthesized via Fmoc-SPPS on a Protein Technologies, Inc. 
Prelude peptide synthesizer.  Pseudoproline dipeptides were obtained from aapptec. 
Multiple batches of each peptide were synthesized at 32 μmol scale.  C-terminal peptides 
(dapA 8 and dapA 7-8) were synthesized on TentaGel R RAM resin (0.19 mmol/g, RAPP 
Polymere).  All other peptides were synthesized on 2-hydrazine chlorotrityl resin 
(ChemPep) loaded manually to a density of 0.05 - 0.1 mmol/g.  2-hydrazine chlorotrityl 
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resin was reproducibly loaded to desired density by dissolving 0.075 mmol amino acid 
and 0.075 mmol Oxyma Pure (Novabiochem) in 1 mL 1:1 DMF:DCM, and activating 
with 0.08 DIC for 10 min before addition to 180 mg of resin.  After a 2 hr coupling, the 
resin is washed with DMF, and unreacted groups on the resin are capped with 1:1 acetic 
anhydride:0.6 M NMM in DMF for 15 min.  Automated synthesis was performed with 
the following parameters: Deprotection: 20% piperidine/DMF for 3 x 3 min; Coupling: 
[1.3/1.3/1] of [200 mM Fmoc-protected amino acid in NMP/198 mM HATU in DMF/600 
mM NMM in DMF]  for 25 min; Washing: 6 x 30 sec with DMF; Cleavage: 
[92.5/2.5/2.5/2.5] of [TFA/water/TIS/EDT] (15 mg/ml NH4I is included in the cocktail 
for methionine-containing peptides) for 2.5 hrs. The cocktail is isolated from the resin, 
concentrated, and precipitated/washed with cold diethyl ether.   
 
Peptide ligation 
For a typical ligation, the N-terminal peptide fragment was dissolved (0.8-3 mM) 
in activation buffer (6 M GuHCl, 100 mM sodium phosphate, pH 3) and chilled to -20ºC.  
Hydrazide activation was accomplished by adding sodium nitrite to a final concentration 
of 5-20 mM (lower concentrations were found to diminish hydrolysis of dapA 2 
thioester) from a 200 mM stock in water (pH adjusted to 4), mixing, and incubating at -
20ºC for 20-30 min.  The C-terminal peptide fragment was dissolved (~2x molar excess 
of N-terminal fragment, except in the case of dapA 5-8 where an excess of dapA 1-4 was 
used) in ligation buffer (6 M GuHCl, 200 mM 4-mercaptophenylacetic acid, 200 mM 
sodium phosphate, pH 7).  In ligations involving dapA 2, 3, and 6, the GuHCl 
concentration was increased to 8 M to enhance peptide solubility.  Following activation 
of the N-terminal fragment, the solutions containing N- and C-terminal fragments were 
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combined, pH adjusted to 7 with NaOH with rapid mixing, and allowed to react at 25ºC 
for 5-20 hrs.  Following ligation, TCEP was added, without pH adjustment, to ~130 mM 
and incubated for 10 min.  The volume was increased to 2.5 mL with 6 M GuHCl in 5% 
AcOH, then brought to 5 mL with 5% AcOH.  The sample was sonicated, clarified via 
centrifugation, and purified by HPLC. 
 
Desulfurization 
Desulfurization was based on (23) with the modification of replacing tBuSH with 
glutathione (33).  Desulfurization buffer (6 M GuHCl, 100 mM phosphate, pH 6.5) was 
sparged with He and used to prepare a 550 mM stock of TCEP (pH re-adjusted with 
NaOH to 6.5 after the addition of TCEP) and a 53 mM stock of reduced glutathione.  A 
240 mM stock of VA-044 was prepared in sparged water.  Peptide was dissolved in 230 
μL of desulfurization buffer at a concentration of  ~3 mM.  Reagents were added to the 
peptide solution in the following order: 204 μL glutathione stock, 204 μL VA-044 stock, 
720 μL TCEP stock.  The reaction was layered with argon and incubated on a tube 
rotisserie overnight at 37ºC.  The reaction was diluted to 2.5 mL with 6 M GuHCl in 5% 
AcOH, mixed, then diluted to 5 mL with 5% AcOH.  The peptide was purified via HPLC. 
Acm deprotection 
Acm deprotection was performed as described in (34) by adding AgOAc to HPLC 
fractions containing Acm-protected peptide to a final concentration of 20 mM, covering 
with argon, and incubating overnight with gentle agitation at 25ºC.  DTT was added to 24 
mM to quench the reaction, which resulted in an immediate metal-DTT precipitate.  
Samples were clarified via centrifugation, diluted with 0.1% TFA in water (to reduce 
acetonitrile concentration), and purified via HPLC. 
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HPLC and LC/MS 
Analytical reverse-phase HPLC was performed on Phenomenex Jupiter 4 μm 
Proteo C12 90 Å (150 x 4.6 mm) and Phenomenex Jupiter 5 μm C4 300 Å (150 x 4.6 
mm) columns at 1 mL/min with a water/acetonitrile gradient in 0.1% TFA.  Preparative 
reverse-phase HPLC was performed on either Phenomenex Jupiter 4 μm Proteo C12 90 
Å (250 x 21.20 mm) or Phenomenex Jupiter 10 μm C4 300 Å (250 x 21.20 mm) at 10 
mL/min with a water/acetonitrile gradient in 0.1% TFA (for crude peptides), or on a 
Phenomenex Jupiter 10 μm C4 300 Å (250 x 10 mm) at 5 mL/min with a 
water/acetonitrile gradient in 0.1% TFA (for ligation products).  Mobile phase was 
removed via lyophilization.  LC/MS was performed with a Phenomenex Aeris 
WIDEPORE 3.6 μm C4 (50 x 2.1 mm) column at 0.4 mL/min with a water/acetonitrile 
gradient in 0.1% formic acid on an AB Sciex API 3000 LC/MS/MS system.   
 
Arginine-assisted refolding 
dapA constructs were dissolved or buffer exchanged into denaturation buffer (6 M 
GuHCl, 20 mM MOPS pH 7.4, 100 mM KCl, 10 mM MgCl2, 10 mM DTT) with 0.5 M 
arginine, equilibrated to 13ºC, and dialyzed (Slide-A-Lyzer mini dialysis cassettes 3500 
MWCO) against 100x volume of refolding buffer (20 mM MOPS pH 7.4, 100 mM KCl, 
10 mM MgCl2, 10 mM sodium pyruvate, 1 mM DTT) with 0.5 M arginine for 2.5 hrs at 
13ºC.  The sample was then further dialyzed against 100x volume 100 mM ammonium 
bicarbonate for 1 hr.  The dialyzed sample was used directly in assays or further purified 
by size exclusion chromatography (Superdex 200 10/30, GE Healthcare) in 100 mM 
ammonium bicarbonate (pH 8) running buffer with a flow rate of 0.75 mL/min. 
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dapA refolding assay 
The dapA refolding assay was adapted from (6).  25 μM stocks of dapA proteins 
were prepared from lyophilized powder or buffer exchanged into denaturation buffer (20 
mM MOPS pH 7.4, 100 mM KCl, 10 mM MgCl2, 10 mM DTT, 6 M GuHCl) and 
allowed to denature for 1 hr at 25ºC.  Refolding was initiated by diluting 100x into 37ºC 
refolding buffer (20 mM MOPS pH 7.4, 100 mM KCl, 10 mM MgCl2, 10 mM sodium 
pyruvate, 5 mM ATP) with or without 7 μM GroEL monomer +/- 7 μM GroES 
monomer.  At specific time points, 10 μL aliquots of the refolding reaction were added to 
240 μL of assay buffer (200 mM Imidazole pH 7.4, 35 mM Na Pyruvate, 4 mM DL-
aspartate-β-semialdehyde, 0.5 mg/mL o-aminobenzaldehyde, 12.5 mM CDTA), which 
simultaneously quenches chaperone-mediated refolding and initiates assay of enzyme 
activity.  The assay is quenched after 15 min of agitation on a microplate shaker (800 
RPM) by the addition of 50 μL 2 M HCl, developed by continuing the agitation for 1 hr., 
followed by measuring the A562.  
 
DL-Aspartate-β-semialdehyde 
DL-aspartate-β-semialdehyde for use in refolding assays was prepared essentially 
as described by Black and Wright (35) from DL-allylglycine except that the purification 
on Dowex resin was omitted and the compound was aliquoted and stored in 1 M HCl at -
80ºC.  Stocks were neutralized with NaOH immediately before preparation of assay 
buffer.   
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Circular dichroism 
All CD spectra were recorded on an AVIV Model 410 spectrophotometer    
(AVIV, Lakewood, NJ) in 100 mM ammonium bicarbonate buffer in a 1 mm QS quartz 
cuvette (Starna) at 25ºC.  Wavelength scans were performed at 1 nm resolution with 1 
second averaging time.  Data from triplicate scans were averaged, blank subtracted, and 
normalized to mean residue ellipticity by the following equation: [θ] = 100*θ/C*l*(n-1) 
where C is concentration of protein in mM, l is pathlength in cm, and n is the number of 
residues in the protein.   
 
Sequence analysis 
BLAST analysis was performed using the BLASTp algorithm with default 
parameters with the dapA protein sequence from E. coli BL21(DE3) (GenBank: 
ACT44191.1).  The sequences were aligned with the COBALT Constraint-based 
Multiple Protein Alignment Tool (36) and analyzed with Jalview (37). 
 
Structural analysis 
The crystal structure of dapA (PDB ID: 1DHP) was analyzed using the Pymol 
Molecular Graphics System, Schrödinger, LLC. 
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Figure 6.1. Sequence and structure of dapA. a, Sequence of our 312-residue dapA 
construct.  Native dapA (292-residues) was prepended with an N-terminal hexahistidine 
tag with a thrombin cleavage site (residues -20 to -1).  All native Cys residues (red) and 
two Ala residues used as ligation junctions (blue) are highlighted.  b, Crystal structure of 
dapA (PDB ID: 1DHP), with one dapA monomer shown in green as a ribbon diagram. 
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Figure 6.2. Comparison of dapA wt and dapA A57C. a, refolding of dapA wt and 
dapA A57C in the presence or absence of GroEL/ES.  b, Enzymatic activity of native 
dapA wt and dapA A57C.  Error bars indicate sd. 
 
 
 
 
Figure 6.3. Peptide fragments used in initial and final assemblies.  Peptides, 
corresponding residue numbers (numbered according to Fig. 6.1b), and sequences of 
fragments used in initial and final assembly strategies.  Native Cys (red), A57C mutation 
(purple), Cys residues introduced at native alanine sites for ligation that were later 
converted back to alanine through desulfurization (blue), and locations where 
pseudoproline dipeptides were incorporated (green) are highlighted.  
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Figure 6.4. Initial dapA assembly strategy. The initial assembly scheme employed in 
the synthesis of L-dapA A57C (PDB structure 1DHP). 
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Figure 6.5.  dapA 2 thioester hydrolysis. The left column shows three points of a time 
course of monitoring dapA 2-MPAA (an active thioester) via LC/MS.  The appearance of 
a second peak in the 30-min time point is due to hydrolysis from dapA 2-MPAA to dapA 
2-COOH.  For comparison, the stability of dapA 5-MPAA is presented in the right 
column.  No significant hydrolysis is noted after O/N incubation for dapA 5-MPAA 
whereas dapA 2-MPAA is fully hydrolyzed (data not shown).   
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Figure 6.6. Sequence and structural analysis of the dapA A57C mutation. a, Natural 
sequence diversity at position 57 from the BLAST analysis. b, Structure of dapA tetramer 
(PDB: 1DHP) showing (on one subunit) the surface-exposed alanine at position 57 
(cyan).  Natural cysteine residues (green) and the catalytic K161 residue in the active site 
(red) are also shown. 
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Figure 6.7. Longer initial peptide fragments via SPPS.  Analytical C4 RP-HPLC 
traces of crude (left) and purified (right) longer dapA fragments synthesized via SPPS.  a, 
dapA 1-2. b, dapA 3-4.  c,  dapA 5-6. d, dapA 7-8. Mass spectra inset on purified 
chromatograms.  Locations of pseudoproline dipeptides highlighted in green. 
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Figure 6.8. Streamlined dapA assembly strategy. This simplified assembly of synthetic 
L-dapA depends on incorporation of the A57C mutation and longer starting peptides. 
 
 
 
 
Figure 6.9. Synthetic dapA assembly. Final assembly scheme employed in the synthesis 
of L- and D-dapA A57C (PDB structure 1DHP). 
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Figure 6.10. Characterization of synthetic dapA. a, analytical C4 reverse-phase HPLC 
of purified recombinant and synthetic dapA.  b-c, mass spec data for synthetic L-/D-
dapA. 
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Figure 6.11. Characterization of assembly intermediates of L-dapA. Analytical RP-
HPLC traces and mass spectra of individual peptides and ligation intermediates 
constructed for the synthesis of L-dapA.  All traces were obtained on a C4 column, 
except dapA 5, dapA 5-6 (Acm), and desulfurized dapA 5-6 (Acm) (C12 column). 
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Figure 6.12. Characterization of assembly intermediates of D-dapA. Analytical RP-
HPLC traces (C4 column) and mass spectra of individual peptides and ligation 
intermediates constructed for the synthesis of D-dapA A57C.  
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Figure 6.13. Arginine-assisted refolding of dapA. a, Schematic overview of arginine-
assisted refolding protocol.  b, Comparison of native recombinant dapA A57C activity 
() to recovered activity following arginine-assisted refolding with L-arginine () or D-
arginine ().  Activity is normalized to native recombinant protein.  Error bars indicate 
s.d. of at least three independent assays. 
 
 
 
Figure 6.14. SEC purification of dapA following arginine-assisted refolding. 
Chromatograph from purification of arginine-assisted refolded synthetic L-dapA A57C (-
) and D-dapA A57C (- and -) run on size-exclusion column (Superdex 200).  Native 
recombinant dapA A57C tetramer () species (normalized) is shown for comparison.    
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Figure 6.15. Structural and functional characterization of synthetic dapA 
constructs. a, Circular dichroism spectra of SEC-purified recombinant (), synthetic L-
dapA (), and D-dapA () (the D-dapA spectrum has been multiplied by -1 to aid direct 
comparison with the other data).  b, Activity of native recombinant dapA () and SEC-
purified synthetic L-dapA () and D-dapA ().  Error bars indicate s.d. of at least three 
independent assays. 
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Figure 6.16.  GroEL/ES-mediated refolding of synthetic dapA constructs.  Refolding 
of synthetic L-dapA () and D-dapA () in the presence (closed circles) or absence 
(open circles) of GroEL/ES, normalized to the GroEL/ES-refolded recombinant dapA 
A57C activity level.  Representative data shown from duplicate experiments. 
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